Cover Page 
Study title:  A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled, Single Site, Exploratory Trial to Assess 
the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal 
Fibrosing Alopecia  
LEO Pharma number: EXP-[ADDRESS_209611] number: [STUDY_ID_REMOVED]
Date: 17-Nov-2021 
Sponsor – Protocol #  Page [ADDRESS_209612] OF DELGOCITINIB CREAM 20 mg/g ON THE 
MOLECULAR SIGNATURE , SAFETY, AND EFFICACY  IN ADULTS 
WITH FRONTAL FIBROSING ALOPECIA  
 
PROTOCOL  EXP -2228  
FINAL  
 
VERSION 2.0 
17 November  2021  
Sponsor:  LEO Pharma A/S  
Industriparken 55  
DK-2750 Ballerup  
Denmark  
Sponsor Medical 
Expert:   [CONTACT_28839], PhD;  Translational 
Medicine  
 
Sponsor 
Representatives :  MD, PhD; Translational 
Medicine  
 MD;  Medical Sciences  
 MSc Stat,  Medical Sciences  
 MSc Pharm,  
Global Clinical Operations  
Clinical Research 
Organization:  
  
 
TMF-000674983 - Version 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
LEO  Pharma A /S – Protocol EXP -2228  Page 2 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  TABLE OF CONTENT S 
TABLE OF CONTENTS  ................................ ................................ ................................ ................  2 
PROTOCOL VERSION HISTORY  ................................ ................................ ...............................  6 
STATEMENT OF COMPLIANCE  ................................ ................................ ................................  8 
SIGNATURE [CONTACT_1783]  ................................ ................................ ................................ ......................  9 
PRINCIPAL/QUALIFIED INVESTIGATOR SIGNATURE [CONTACT_1783]  ................................ ..........  [ADDRESS_209613] OF ABBREVIATIONS  ................................ ................................ ................................ ....... 12 
1 PROTOCOL SUMMARY  ................................ ................................ ............................  14 
1.1 Synopsis  ................................ ................................ ................................ ........................  14 
1.2 Trial Diagram  ................................ ................................ ................................ ................  23 
1.3 Schedule of Events  ................................ ................................ ................................ ........  23 
2 INTRODUCTION  ................................ ................................ ................................ ........  30 
2.1 Background  ................................ ................................ ................................ ...................  30 
 Frontal Fibrosing Alopecia  ................................ ................................ ..................  30 
 Delgocitinib ................................ ................................ ................................ ...........  30 
 Trial Rationale  ................................ ................................ ................................ ...... 31 
2.2 Risk/Benefit Assessment  ................................ ................................ ...............................  31 
 Known Potential Risks  ................................ ................................ ..........................  31 
 Known Potential Benefits  ................................ ................................ ......................  32 
 Assessment of Risks and Benefits  ................................ ................................ ..........  32 
 COVID -19 Pandemic  ................................ ................................ ............................  32 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ..............  34 
4 TRIAL DESIGN  ................................ ................................ ................................ ...........  36 
4.1 Overall Design  ................................ ................................ ................................ ..............  36 
4.2 Scientific  Rationale for Trial Design  ................................ ................................ ............  38 
4.3 Justification for Dose  ................................ ................................ ................................ .... 38 
4.4 End of Trial Definition  ................................ ................................ ................................ .. 39 
5 TRIAL POPULATION  ................................ ................................ ................................ . 40 
5.1 Inclusion Criteria  ................................ ................................ ................................ ...........  40 
5.2 Exclusion Criteria  ................................ ................................ ................................ .........  41 
5.3 Lifestyle Considerations  ................................ ................................ ...............................  43 
5.4 Screen Failures  ................................ ................................ ................................ ..............  44 
6 TREATMENT  ................................ ................................ ................................ ..............  45 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 3 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  6.1 Trial Treatment Administered  ................................ ................................ .......................  45 
 Treatment Interruption ................................ ................................ ..........................  45 
6.2 Preparation/Handling/Storage/Accountability  ................................ ..............................  46 
 Preparation/Storage/Handling  ................................ ................................ .............  [ADDRESS_209614] to Fo llow-Up ................................ ................................ ................................ .........  52 
8 TRIAL ASSESSMENTS AND PROCEDURES  ................................ .........................  53 
8.1 Efficacy Assessments (Cohort 1 only)  ................................ ................................ ..........  53 
 Lichen Planopi[INVESTIGATOR_178370]  ................................ ................................ ........  53 
 Frontal Fibrosing Alopecia Severity Score  ................................ ..........................  53 
 Perifollicular Erythema and Scale ................................ ................................ ........  53 
 Pruritus Numerical Rating Scale  ................................ ................................ ..........  54 
 Burning Sensation Numerical Rating Scale  ................................ ..........................  54 
 Pain Numerical Rating Scale  ................................ ................................ ................  54 
 Hair Counts/Trichoscopy  ................................ ................................ ......................  54 
 Hair Line Measurements ................................ ................................ .......................  55 
8.2 Safety Assessments  ................................ ................................ ................................ ....... 55 
 Vital Signs  ................................ ................................ ................................ .............  55 
 Complete Physical Examination  ................................ ................................ ...........  55 
 Brief Physical Examination  ................................ ................................ ..................  55 
 Clinical Laboratory Tests  ................................ ................................ .....................  56 
 Electrocardiogram  ................................ ................................ ................................  57 
 Loca l Tolerability Assessments  ................................ ................................ .............  57 
8.3 Pharmacodymanic Assessments  ................................ ................................ ...................  57 
 Skin Biopsies  ................................ ................................ ................................ .........  58 
 Tape Strippi[INVESTIGATOR_007]  ................................ ................................ ................................ ....... 58 
 Skin Swabs for Microbiomes Analysis  ................................ ................................ .. 59 
8.4 Other Assessments  ................................ ................................ ................................ ........  59 
 Target Area Identification ................................ ................................ .....................  59 
 Medical Photography ................................ ................................ ............................  60 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 4 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  8.5 Adverse Events and Serious Adverse Events (Cohort 1 Only)  ................................ ..... [ADDRESS_209615] (AESI)  ................................ .............................  66 
 Medication error  ................................ ................................ ...............................  66 
 Misuse or Abuse  ................................ ................................ ................................  67 
 Aggravation of condition  ................................ ................................ ..................  67 
8.6 Procedural Complications (Cohort 2 Only)  ................................ ................................ .. 67 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ..........  69 
9.1 Sample Size Determination  ................................ ................................ ...........................  69 
9.2 Populations for Analyses  ................................ ................................ ..............................  69 
9.3 Statistical Analyses  ................................ ................................ ................................ ....... 70 
 General Approach  ................................ ................................ ................................ . 70 
 Baseline  ................................ ................................ ................................ .................  70 
 Efficacy Ana lyses  ................................ ................................ ................................ .. 71 
 Safety Analyses ................................ ................................ ................................ ...... 72 
 Molecular Signature [CONTACT_178483]  ................................ ...............................  73 
 Other Analyses  ................................ ................................ ................................ ...... 73 
 Planned Interim Analyses  ................................ ................................ .....................  74 
10 REGULATORY, ETHICAL, AND TRIAL OVERSIGHT CONSIDERATIONS  ...... 75 
10.1  Local Regulations/Declaration of Helsinki  ................................ ................................ ... [ADDRESS_209616] Keepi[INVESTIGATOR_007]  ................................ ................................ .............  77 
10.9  Protocol Deviations  ................................ ................................ ................................ ....... 78 
10.10  Publication Policy  ................................ ................................ ................................ .........  78 
11 REFERENCES  ................................ ................................ ................................ ..............  79 
APPENDIX A: Lichen Planopi[INVESTIGATOR_178370] (LPPAI) 7 ................................ ....................  80 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 5 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX B: Frontal Fibrosing Alopecia Severity Score 8 ................................ .......................  81 
APPENDIX C: Numerical Rating Scale  ................................ ................................ .......................  [ADDRESS_209617] OF TABLES  
 
Table 1: Schedule of Events for Cohort 1 (Subjects with FFA)  ................................ ...................  25 
Table 2: Schedule of Events for Cohort 2 (Healthy Subjects)  ................................ ......................  29 
Table 3: Trial Treatments ................................ ................................ ................................ ..............  45 
Table 4: Prohibited Therapi[INVESTIGATOR_178371] 1 (Subjects with FFA)  .........................  49 
Table 5: Prohibited Therapi[INVESTIGATOR_178371] 2 (Healthy Subjects)  ............................  50 
Table 6: P erifollicular Erythema and Perifollicular Scale Severity Scale  ................................ .... 54 
Table 7: Clinical Laboratory Testing (Cohort 1)  ................................ ................................ ..........  56 
Table 8: Subject Assessment of Local Tolerability after IMP Application  ................................ .. [ADDRESS_209618] OF FIGURES  
 
Figure 1: Trial Diagram  ................................ ................................ ................................ ................  23 
 
 
 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 6 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  PROTOCOL VERSION HISTORY  
Version  Rational e for amendment  Main changes to the protocol  
1.0 / 03 June 2021  Initial version  N/A 
2.0 / 17 November 2021  To change the Sponsor Medical 
Expert  - Cover page and Signature [CONTACT_3264]: The 
Sponsor Medical Expert [INVESTIGATOR_178482] 1:  
 
- To modify the safety 
monitoring during the 
open -label extension (OLE) 
so that subjects who initiate 
delgocitinib will be 
monitored similarly, whether 
they initiate delgocitinib 
during the OLE or the initial 
treatment period.  
 
 
 
 
 
 
- To add the approximate 
dimension of the lesional 
target area and to specify that 
tape strippi[INVESTIGATOR_178372].  
 
 
 
 
 
 
 
- To evaluate thyroid function 
at screening  
 
 
 
 
 
  
- To allow treatment of the 
eyebrows, if affected  
 
 
  
 
 
- Synopsis, Section 1.3 (Table 1), 
Section  4.1, Section 8.2.4, and 
Section 8.2.6: The phone call visits 
planned at Week 16 and Week 20 
were changed to on -site visits. 
Therefore, subjects will come to the 
site on 9  occasions, including at 
Week 16 and Week 20. All 
assessments that were to be 
performed at the phone call visits will 
be done at the site. Some additional 
safety, efficacy, and other 
assessments were added at Week 16 
and Week 20 visits.  
 
- Synop sis, Section 1.3 (Table  1, 
footnote s c and k ), Section 4.1, 
Section  8.1.7, Section 8.3, and 
Section 8.4.1: Clarifications added 
regarding selection of the lesional 
target area(s), including dimension. 
Clarifications added regarding which 
assessments could and could not 
overlap on the lesional target area(s). 
Specifications added for the tape 
strippi[INVESTIGATOR_178373].  
 
- List of abbreviations, Synopsis, 
Section 1.3 (Table 1), Section  5.2, 
and Section 8.2.4: Added thyroid -
stimulating hormone ( TSH) with 
reflex free T4 at screening and related 
exclusion criterion (Exclusion 
Criterion #14). 
 
- Section 5.3 and Section 6.1: Clarified 
that all affected areas on the 
face/scalp can be treated, including 
the eyebrows , if affected . If eyebrows 
are treated, subjects should absta in 
TMF-000674983 - Version 2.0
[COMPANY_003]
LEO  Pharma A /S – Protocol EXP -2228  Page 7 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.   
 from wetting them within 2 hours 
following IMP application.  
To add the outcome categories of 
adverse events (AEs).  
 - Section 8.5.4: Added the different 
outcome categories of AEs under a 
new section [IP_ADDRESS].  
To clarify that the Numerical 
Rating Scale questions (pruritus, 
burning sensation, and pain) will 
be specific to frontal fibrosing 
alopecia.  - Appendix C: Modified the NRS 
questions so that the three questions 
are specific to frontal fibrosing 
alopecia.  
To add the Innovaderm project 
team contact [CONTACT_178429].  - Section 8.5.7: Added the Innovaderm 
project team e -mail address.  
To clarify that the use of systemic  
or topi[INVESTIGATOR_178374] [ADDRESS_209619] agrees 
to continue using it on a stable dos ing 
during the present study  (Exclusion 
Criterion #19 and #20) .  
To clarify the restrictions to be 
followed by [CONTACT_178430] r 
stable dose of topi[INVESTIGATOR_178375].   - Section 5.3, the following note was 
added : In addition, for the subjects 
who are on stable dose of topi[INVESTIGATOR_178376] 6 months prior 
to Day  1 and continue using it during 
the study, they should be instructed to 
not apply it on the areas where skin 
samples will be collected on the visit 
days before the visit.  
 
 
 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 8 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  STATEMENT OF COMPLIANCE  
The trial will be conducted in accordance with the protocol, International Council for 
Harmonisation (ICH) Good Clinical Practice (GCP), and applicable local regulations . The 
principal investigator [INVESTIGATOR_178377], or changes to the protocol will 
take place without prior agreement from the sponsor and documented approval from the 
institutional review board (IRB) /research ethics board (REB) , except where necessary to eliminate 
an immediate hazard(s) to the trial subjects . All personnel involved in the conduct of this trial have 
completed ICH GCP training.  
The protocol, informed consent form(s), recruitment materials, and all subject materials will be 
submitted to the IRB /REB  for review and approval. Approval of both the p rotocol and the consent 
form must be obtained before any subject is enrolled. Any amendment to the protocol will require 
review and approval by [CONTACT_1201] /REB  before the changes are implemented to the trial. All changes 
to the consent form will be IRB /REB  approved.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 9 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  SIGNATURE [CONTACT_178484], applicable local regulations , and ICH 
GCP  guidelines . 
 
 
 
Sponsor:   
  MD, PhD  
 Translational Medicine  
LEO Pharma A/S 
 
 
 
 
  Date (DD-MMM -YYYY)  
  MD, PhD   
 Translational Medicine  
LEO Pharma A/S  
 
 
 
 
  Date (DD-MMM -YYYY)  
  MD  
 Medical Sciences  
LEO Pharma A/S  
 
 
 
 
  Date (DD-MMM -YYYY)  
  MSc Stat   
 Medical Sciences  
LEO Pharma A/S  
 
 
 
 
  Date (DD-MMM -YYYY)  
  MSc Pharm   
 Global Clinical 
Operations  
LEO Pharma A /S  Date (DD-MMM -YYYY)  
18-Nov-2021 | 14:52:[ADDRESS_209620]
22-Nov-2021 | 10:08:[ADDRESS_209621]
22-Nov-2021 | 07:56:[ADDRESS_209622]
22-Nov-2021 | 10:58:[ADDRESS_209623]
22-Nov-2021 | 11:22:[ADDRESS_209624]
TMF-000674983 - Version 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
LEO  Pharma A /S – Protocol EXP -2228  Page 10 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  SIGNATURE [CONTACT_1783] (Continued)  
 
 
 
 
 
Scientific  Affairs : 
 
  BSc  
 Scientific and Regulatory Affairs   
Innovaderm Research Inc.   Date (DD-MMM -YYYY)  
 
 
 
 
 
Biometrics :  
 
 , MSc  
 Biomet rics 
Innovaderm Research Inc.  
 
 
 
 
  Date (DD-MMM -YYYY)  
 
 
 
 
 
22-Nov-2021 | 11:40:[ADDRESS_209625]
22-Nov-2021 | 12:43:[ADDRESS_209626]
TMF-000674983 - Version 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
TMF-000674983 - Version 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
LEO  Pharma A /S – Protocol EXP -2228  Page 12 of 82  
Final Protocol Version 2.0: [ADDRESS_209627] research organization  
CXCL9  chemokine (C -X-C motif) ligand 9  
CXCL10  chemokine (C -X-C motif) ligand 10 
EASI  Eczema Area and Severity Index  
EASI75  a 75% reduction in EASI  score  
ECG  Electrocardiogram  
eCRF  electronic case report form  
eHFSC  epi[INVESTIGATOR_178378] -glutamyl -transferase  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCT  Hematocrit  
HCV  hepatitis C virus  
Hgb Hemoglobin  
HIV human immunodeficiency virus  
HFIP  hair follicule immune privilege  
IB Investigator Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IHC Immunohistochemistry  
IMP investigational medicinal product  
INF Interferon  
IRB institutional review board  
JAK Janus kinase  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 13 of 82  
Final Protocol Version 2.0: [ADDRESS_209628]  upper limit of normal  
UV Ultraviolet  
vIGA -AD TS  Validated Investigator Global Assessment for Atopic Dermatitis 
treatment success  
WBC  white blood cell  
WOCBP  women of childbearing potential  
WHO  world health organization  
 
 
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 14 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  1 PROTOCOL SUMMARY  
1.1  Synopsis   
Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
Title of Trial :  
A Phase 2a, Randomized, Double -Blind, Vehicle -Controlled, Single Site, Exploratory Trial  to Assess 
the Effect of Delgocitinib Cream 20 mg/g o n the Molecular Signature , Safety, and Efficacy  in Adults 
with Frontal Fibrosing Alopecia  
Phase of Development:  
Phase 2a  
Trial  Site:  
This trial will be conducted at 1  site located in the [LOCATION_002]   
[LOCATION_011], MA ). 
Number of Subjects (planned):  
• Cohort 1  
- Approximately 30 subjects with frontal fibrosing alopecia (FFA) will be randomized in this 
cohort.  
• Cohort 2  
- Approximately 5 healthy postmenopausal female subjects will be included in this cohort.  
Duration of Trial :  
• Cohort [ADDRESS_209629] is approximately 30 weeks, including up to 3 0 days 
for the screening period, 12 weeks for the vehicle -controlled t reatment period, 12 weeks for 
the open -label extension (OLE), and approximately 2 weeks for the safety follow -up period.  
• Cohort [ADDRESS_209630], Dosage, and Mode of Administration:  
Delgocitinib  cream 20 mg/g and matching vehicle  (delgocitinib cream vehicle) . 
•  Cohort 1  
- Subjects will be randomized in a 1:1 ratio on Day 1 to  apply  delgocitinib cream  20 mg/g or 
vehicle cream twice daily (BID) for 12 weeks  during the vehicle -controlled treatment period . 
TMF-000674983 - Version 2.0
[COMPANY_003]
LEO  Pharma A /S – Protocol EXP -2228  Page 15 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
After the vehicle -controlled treatment period, subjects will continue into the OLE and will 
apply  delgocitinib cream 20 mg/g BID for 12 weeks.  
• Cohort [ADDRESS_209631] will be administered in Cohort 2 . 
Objectives:  
Primary:  
The primary objective is : 
• To assess molecular signature [CONTACT_178485][INVESTIGATOR_178379] 20 mg/g 
in subjects with FFA . 
Secondary:  
The secondary objective is:  
• To evaluate the safety and tolerability of delgocitinib cream 20 mg/g following topi[INVESTIGATOR_178380] -controlled treatment period . 
Exploratory:  
The exploratory objective s are: 
• To evaluate the safety and tolerability of  delgocitinib cream 20 mg/g during the OLE . 
• To evaluate the preliminary efficacy of delgocitinib cream 20 mg/g following topi[INVESTIGATOR_178381] . 
Endpoints:  
Primary Endpoint:  
• Change in expression of chemokine (C -X-C motif) ligand 9 (CXCL9), chemokine (C -X-C motif) 
ligand 10 (CXCL 10), and interferon (IFN) -γ from baseline to Week 12 . 
Secondary Endpoint:  
• Number of treatment -emergent adverse events (TEAEs)  from baseline to Week 12.  
Exploratory Endpoints:  
Exploratory safety endpoint:  
• Number of TEAEs  during the OLE  (up to Week 26)  
Exploratory e fficacy endpoints during the vehicle -controlled treatment period:  
• Change in Lichen Planopi[INVESTIGATOR_178370] (LPPAI) score from baseline to Weeks 4, 8, and 12. 
• Change in Frontal Fibrosing Alopecia Severity Score (FFASS)  from baseline to Weeks 4, 8, and 
12. 
• Change in target area perifollicular erythema score from baseli ne to Weeks 4, 8, and 12. 
• Change in target area perifollicular scale score from baseline to Weeks 4, 8, and 12. 
• Change in pruritus Numerical Rating Scale (NRS) score from baseline to Days 2, 3, 4, 5, 6 , 7, 8, 
and Weeks 4, 8, and 12. 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 16 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
• Change in burning sensa tion NRS score from baseline to Days 2, 3, 4, 5, 6, 7, 8, and Weeks 4, 8,  
and 12. 
• Change in pain NRS score from baseline to Days 2, 3, 4, 5, 6, 7, 8, and Weeks 4, 8, and 12. 
• Proportion of subjects with a 3 -point reduction * in pruritus NRS score from baseli ne to Days 2, 3, 
4, 5, 6, 7, 8, and Weeks 4, 8, and 12. 
• Proportion of subjects with a 4 -point reduction * in pruritus NRS score from baseline to Days 2, 3, 
4, 5, 6, 7, 8, and Weeks 4, 8, and 12. 
• Proportion of subjects with a 3 -point reduction * in burning sensation NRS score from baseline to 
Days 2, 3, 4, 5, 6, 7, 8, and Weeks 4, 8, and 12. 
• Proportion of subjects with a 4 -point reduction * in burning sensation NRS score from baseline to 
Days 2, 3, 4, 5, 6, 7, 8, and Weeks 4, 8, and 12. 
• Proportion  of subjects with a 3 -point reduction * in pain NRS score from baseline to Days 2, 3, 4, 
5, 6, 7, 8, and Weeks 4, 8, and 12. 
• Proportion of subjects with a 4 -point reduction * in pain NRS score from baseline to Days 2, 3, 4, 
5, 6, 7, 8, and Weeks 4, 8, and 12. 
• Change in target area hair counts/trichoscopy via fotofinder trichovision from baseline to  Week  12. 
Exploratory e fficacy endpoints during the OLE:  
• These efficacy outcomes will be measured at scheduled visits after Week 12: LPPAI, FFASS, 
target area perif ollicular scale score, target area perifollicular erythema score, pruritus NRS, 
burning sensation NRS, pain NRS, and target area hair counts/trichoscopy via fotofinder 
trichovision.  
* Note: Only subjects with a baseline NRS score ≥3 will be included in the respective endpoints on proportion of 
subjects with a 3 -point reduction. Only subjects with a baseline NRS score ≥4 will be included in the respective 
endpoints on proportion of subjects with a 4 -point reduction.  
Trial  Design:  
A Phase 2a, randomized, double -blind, vehicle -controlled, single -site, exploratory trial of delgocitinib 
cream  20 mg/g  in subjects with FFA.  
The trial will consist of 2 cohorts: Cohort 1 will include approximately  30 subjects with FFA and 
Cohort  2 will include approxi mately 5 healthy postmenopausal female subjects. Both cohorts can be 
conducted in parallel.  
Cohort 1:  
All subjects will read and sign an informed consent form (ICF) prior to any trial-related activities  being 
performed. Subjects who fulfill all of the inclusion criteria and none of the exclusion criteria will be 
randomized into the trial. After a screening period of no more than 30 days (from Day -30 to Day -1), 
eligible subjects will be randomized (1:1)  on Day 1 to apply  delgocitinib cream  20 mg/g  or vehicle cream  
BID for 12 weeks  during the vehicle -controlled treatment period . All subjects who complete the 
vehicle -controlled treatment period will then continue into the OLE and apply delgocitinib cream 
20 mg/g  BID for 12 weeks . The OLE  period will be followed by a 2-week safety follow -up period. For 
scheduled trial visits, subjects will come to the site on 9 occasions: screening, Day 1, Week  4, Week 8 , 
Week 12, Week 16, Week 20,  Week 24, and Week 26/early termination ( ET).  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 17 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
On Day 1, a lesional target area on the scalp (eg, frontal, periauricular , or temporal area) that will be 
treated with the investigational medicinal product (IMP)  will be identified. To allow for the hair 
count/trichoscopy assessment and all samples collection (ie, skin biopsies, tape strippi[INVESTIGATOR_007], and skin 
swabs) the lesional target area should be approximately 3 cm x 6 cm  (or equivalent) . However, as tape 
strips c an be collected from the same area w here trichoscopy/hair counts is performed  or can be collected 
adjacent /close  to the lesional  target area (refer to Section 8.3.2 for details), a smaller lesional target area 
may be acceptable . If needed , two small target areas (totalling approximately the same size) could also 
be selected to allow for skin samples collection and hair count/trichoscopy assessment . If two lesional 
target areas are selected, they should be of similar severity.  
The following skin samples will be collected during the trial to assess molecular signature [CONTACT_178486] : 
- Skin biopsies for transcriptomic and immunohistochemistry (IHC)  analys es (n=3):  
o Day 1:  2 skin biopsies ( 4-mm) will be collected prior to the first IMP applicatio n (1 from 
a lesional hair follicle within the target area and 1 from a non lesional hair follicle [eg,  on 
the occipi[INVESTIGATOR_178382]]).  
o Week 12:  1 skin biopsy ( 4-mm)  will be collected from a hair follicle within the lesional 
target area  (outside the scar of previous biops ies). 
- Skin swabs for microbiome  analysis (n=3):  
o Day 1 : [ADDRESS_209632] IMP applicatio n 
(1 from the target area [lesional skin] and 1 from an uninvolved occipi[INVESTIGATOR_178383]).  
o Week 12 : 1 skin microbiome sample will be collected at the same location of the lesional 
skin of the target area.  
- Adhesive tape strips samples for transcriptomic analysis (n=3):  
o Day 1 : skin tape strips will be collected prior to the first IMP applicatio n from lesional 
skin and from non lesional skin (eg,  on the occipi[INVESTIGATOR_178382]).  
o Week 12 : skin tape strips will be colle cted at the same location of the lesional skin.  
Note:  Every effort should be made to collect tape strip samples in all subjects however, 
adhesive tape strip collection is optional and will be collected per investigator ’s judgement 
(based on available skin area  on the scalp ). 
Safety  will be assessed by [CONTACT_178431] ( AEs), recording vital signs, performing complete 
and brief physical examinations, and evaluating clinical laboratory results  and local tolerabilit y 
assessments (LTA) . 
Efficacy will be assessed using  LPPAI, FFASS, evaluation of the perifollicular erythema and 
perifollicular scale, pruritus NRS, burning sensation NRS, pain NRS , and hair counts/trichoscopy 
(eg, number of hairs, hair diameter, and hair density ). Hair line measurements ( ie, lateral canthus [right 
and left] to hairline, lower glabellar crease to hair line, top of frontalis muscle to hair line, and mid brow 
to hair line [right and left]) will also be done.  
Medical ph otographs of the lesional target area and the entire scalp (including the frontal hair line and 
right and left hair line areas) will be taken with the fotofinder device during the trial. 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 18 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
Cohort 2: 
All subjects will read and sign an ICF prior to any trial-related activities  being performed. Subjects who 
fulfill all of the inclusion criteria and none of the exclusion criteria will be accepted into the trial. After 
a screening period of no more than 30 days (from Day -30 to Day -1), eligib le subjects will be asked to 
come at the site for skin samples collection . Screening and skin sample s collection on Day 1 can be 
performed on the same day (if subjects do not have a washout period ) or on two separate visits, at the 
investigator’s discretio n. No investigational product will be administered in Cohort 2 . For scheduled trial 
visits, subjects will come to the site on up to 3  occasions: screening, Day 1, and optional follow -up visit . 
The following skin samples will be collected:  
- Skin biopsies (n=2):  
o Day 1:  2 skin biopsies ( 4-mm) that include hair follicles will be collected on healthy 
skin at similar matched areas of subjects with FFA (ie, 1 from frontal scalp area and 
1 from occipi[INVESTIGATOR_178383])  
- Adhesive tape strips (n=1):  
o Day 1 : skin tape strips will be collected on non-hair bearing healthy skin at a similar 
matched area of subjects with FFA (ie, on the forehead, as close as possible to the  frontal 
scalp area).  
- Skin swabs for microbiome  analysis (n=2):  
o Day 1 : 2 skin microbiome samples will be collected on healthy skin at similar matched 
areas of subjects with FFA (ie, 1 from frontal scalp area and 1 from occipi[INVESTIGATOR_178383] ). 
For Cohort 2 only, s afety will be assessed by [CONTACT_178432] s collection.  
Inclusion/Exclusion Criteria:  
Inclusion criteria:  
In order to be eligible to participate in this trial, a subject must meet all of the following criteria, either 
at the screening and Day 1 visits or only at one of the specified visits (screening or Day 1)  as noted in 
the criterion:  
Inclusion criteria for all subjects:  
1. Subject is willing to participate and is capable  of giving informed consent. Note: Consent must be 
obtained prior to any trial-related procedures.  
2. Subjects must be willing to comply with all trial procedures and must be available for the duration 
of the trial. 
Inclusion criteria for Cohort 1 only (subj ects with FFA):  
3. Male or female subject aged [ADDRESS_209633] has clinically confirmed diagnosis of FFA based on investigator’ s judgment.  
6. Subject has a target area with a perifollicular erythema score ≥ 2 and a perifollicular scale score ≥  2 
at Screening and Day 1.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 19 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
7. For subject who uses make -up, moisturizers, creams, lotions, cleansers, and/or sunscreens  on the 
face, subject has used the same  product brands/types for a minimum period of 4 weeks prior to 
Day 1, agrees not to change brand/type or frequency of use throughout the trial, agrees not to apply 
those products on the treated area during the trial, and agrees not to use make -up, moisturi zers, 
creams, lotions, cleansers, and/or sunscreens on the face on the clinic visit days before the visit.  
8. Subject is willing to maintain a consistent hair style and hair style regimen, including shampoo and 
hair products (including hair dye, process, and timing to hair appointments), and to refrain from 
weaves or extensions throughout the course of the trial and for 4 weeks prior to Day 1.  
Note:  Hair dying and shaving of scalp is allowed during the trial but not within [ADDRESS_209634] of childbearing potential involved in any sexual intercourse that could lead to 
pregnancy: the subject must agree to use an effective contraceptive method from at least [ADDRESS_209635] IMP application . Effective contraceptive methods 
include hormonal contraceptives (eg , combined oral contraceptive, proges terone -only hormonal 
contraception [associated with or without inhibition of ovulation as the primary mode of action], 
patch, vaginal ring, injectable, or implant), intrauterine devices or intrauterine systems, vasectomized 
partner(s) (provided his vasecto my was performed ≥4 months prior to Screening) , tubal ligation or 
a barrier  method of contraception (eg , male condom, female condom, cervical cap, diaphragm, 
contraceptive sponge ) in conjunction with spermicide.  
Note: Subjects must have been on a stable d ose of hormonal contraceptives for at least 4 weeks 
before Day 1.  
Note: The above list of contraceptive methods does not apply to subjects who are abstinent for at 
least [ADDRESS_209636]. Periodic abstinence 
(calendar, symptothermal, post-ovulation methods) is not acceptable.  
Note:  A female subject of nonchildbearing potential is defined as follows:  
– Female subject who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or 
bilateral salpi[INVESTIGATOR_1656])  
– Female subject who h as had a cessation of menses for at least 12 months prior to the screening 
visit without an alternative medical cause  
Inclusion criteria for Cohort 2 only (healthy subjects):  
10. Female subject aged 45 years  of age or older  at the time of consent.  
11. Female is postmenopausal as defined below:  
– Female subject who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or 
bilateral salpi[INVESTIGATOR_1656])  
– Female subject who has had a cessation of menses for at least [ADDRESS_209637] is in good general health, according to the investigator’s judgment based on vital signs , 
medical history , and brief physical examination .   
 
 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 20 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
Exclusion criteria:  
A subject who meets any of the following criteria at the screening and/or Day 1 visits, as applicable, will 
be excluded from participation in this trial: 
Exclusion criteria for all subjects:  
1. Subject is a female who is breastfeeding, pregnant, or who is pla nning to become pregnant during 
the trial. 
2. Subject has received any marketed or investigational biological agent within 12 weeks or 5 half -lives 
(whichever is longer) prior to Day 1.  
3. Subject is currently receiving a nonbiological investigational product or device or has received one 
within [ADDRESS_209638] has had excessive sun exposure or has used tanning booths within 4 weeks prior to Day 1 or 
is not willing to minimize natural and artificial sunlight exposure duri ng the trial. Use of sunscreen 
products (except on treated areas for subjects in Cohort  1) and protective apparel are recommended 
when sun exposure cannot be avoided.  
5. Subject has a history of an allergic reaction or significant sensitivity to lidocaine or other local 
anesthetics.  
6. Subject has a history of hypertrophic scarring or keloid formation in scars or suture sites.  
Exclusion criteria for Cohort 1 only (subjects with FFA):  
7. History of other scalp/hair disease  including discoid lupus erythematosus  and central centrifugal 
cicatricial alopecia . 
Note: Subjects with lichen planopi[INVESTIGATOR_22785]/FFA overlap are not to be excluded.  
8. Presence of active dermatologic condition that might interfere with FFA diagnosis and/or interfere 
with the trial assess ments  such as seborrheic dermatitis , psoriasis , or telogen effluvium . 
9. Subject who has undergone scalp reduction surgery or hair transplantation.  
10. Use of adhesive wigs during the trial. 
11. Subject is known to have immune deficiency or is immunocompromised.  
12. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects 
with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or 
localized carcinoma in situ of the cervix are not to be exclud ed. 
13. Subject had a major surgery within [ADDRESS_209639] has uncontrolled  hypo - or hyperthyroidism  or has both thyroid -stimulating hormone ( TSH) 
and free T4 levels  outside normal range  at screening .   
15. Subject has any clinically significant medical condition or physical/laboratory/ ECG/ vital signs 
abnormality that would, in the opi[INVESTIGATOR_871], put the subject at undue risk or interfere 
with interpretation of trial results.  
16. Subject has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B core 
antigens (anti -HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).  
17. Subject has used treatment with agents (including natural p roducts or nutritional supplement  such as 
Viviscal , Nutrafol, and/or biotin ) that may affect hair regrowth in the last 4 weeks prior to Day 1 . 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 21 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
18. Subject has used intralesional scalp corticosteroids or platelet rich plasma injection in the last 
[ADDRESS_209640] has used systemic treatment with immunosuppressive/modulating medication or medication 
that could affect FFA (eg, corticosteroids, methotrexate, minoxidil, hydroxychloroquine, retinoids, 
calcineurin inhibitor, tetracyclines, pi[INVESTIGATOR_051],  spi[INVESTIGATOR_8407], or 5-α-reductase -inhibitors) within 
4 weeks prior to Day  1.  
Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops 
containing corticosteroids are also allowed.  
Note:  Standard doses of s ystemic antihistamines are allowed.  
Note: Use of systemic treatment with minoxidil  or spi[INVESTIGATOR_178384] 
[ADDRESS_209641] FFA within 2  weeks prior to 
Day 1, including, but not limited to, topi[INVESTIGATOR_11930], calcineurin inhibitors, minoxidil, 
phosphodiesterase -4 (PDE -4) inhibitors.  
Note: Use of topi[INVESTIGATOR_178385] [ADDRESS_209642]  has received treatment with Janus kinase (JAK)  inhibitors (systemic or topi[INVESTIGATOR_2855]) within 
[ADDRESS_209643] has received any ultraviolet (UV) -B phototherapy (including tanning beds), excimer laser, 
or any other phototherapy within [ADDRESS_209644] has had psoralen -UV-A (PUVA) treatment within [ADDRESS_209645] year prior to 
Day 1.  
Exclusion criteria for Cohort 2 only (healthy subjects):  
27. Subject has a history of skin disease or presence of skin condition that, in the opi[INVESTIGATOR_1070], would interfere with the trial assessments.  
28. Subje ct has any clinically significant medical condition or physical/ vital signs abnormality that 
would, in the opi[INVESTIGATOR_871], put the subject at undue risk or interfere with interpretation 
of trial results.  
29. Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or HIV).  
30. Subject has used a topi[INVESTIGATOR_178386] 2 week s prior to skin 
samples collection (Day 1).    
Statistical methods:   
Continuous variables will be summarized in tables and will include the number of subjects, mean, 
standard deviation (SD), median, minimum, maximum , first (Q1) and third (Q3) quartiles . Categorical 
variables will be presented in tables as frequencies and percentages.  
Molecular Signature [CONTACT_178487]:  
A Mixed Effect Model Repeated Measurement (MMRM) will be used to detect any overall differences 
in the treatment effect at Week 12 co mpared to baseline in the molecular measurements. This formulation 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 22 of 82  
Final Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Name [CONTACT_790]/Company:  
LEO Pharma A/S Name [CONTACT_791]: 
Delgocitinib  cream  20 mg/g  Name [CONTACT_3261]: 
Delgocitinib  
intrinsically models the within patient correlation structure as in the case of a paired t -test. This approach 
introduces less bias than restricting the analysis for those patients who comp leted the trial. Time points 
(baseline, Week 12) , treatment group (active, vehicle, and healthy) , and tissue (lesional and non -lesional) 
will be considered as fixed factors, while participant ID will be included as random factor.  
Safety Analyses:   
Safety d ata will be summarized descriptively  per cohort . No missing data will be imputed, and no 
inferential statistics are planned. For Cohort 1, t he safety analysis will include reported AEs , including 
TEAEs,  and other safety information (ie. clinical laboratory evaluations  and vital signs).  For Cohort 2, 
the safety analysis will include reported  procedural complications.  
Efficacy Analyses:   
The comparison between the groups for the exploratory efficacy  endpoint s involving change from 
baseline will be d one using a MMRM , where the absolute change from baseline will be the dependent 
variable; the treatment group, the visit, and an interaction term for the treatment -by-visit will be the fixed 
effects; and the baseline value will be the covariate . 
The other efficacy endpoints involving proportions of pruritus NRS, burning sensation NRS, and pain 
NRS will be analyzed using a Chi-square  test. 
Sample Size Consideration:  
From Del Duca et al. (2020) paper1, the difference in log2 -fold changes (SD*) between FFA patients and 
healthy controls are reported to 4.851 (4.411), 5.298 (5.512) and 4 .559 (4.891) for CXCL9, CXCL10 
and IFN -γ, respectively.  
A sample 30 subjects are randomized  in an equal manner (1:1) to delgocitinib cream 20 mg/g or vehicle  
cream . It is expected that a reduction of at least 90% from baseline to Week 12 for the delgocitin ib cream 
20 mg/g treated subjects compared to only 5% in the vehicle group, normalized  to healthy controls, will 
be observed.  
With the above assumptions, the trial should have at least 80% disjunctive power, i.e. a statistically 
significant difference (tes ted at 5% one -sided level in an independent two -sample t -test) can be shown 
with at least 80% probability, in at least one of the genes, assuming no correlation between the tests and 
same level of variation  as reported in the Del Duca et al. (2020) paper1. 
 
*Derived from the reported p -values coming from a t-test comparing lesional FFA biopsy data (N=12) to data from 
healthy controls (N=8) . 
 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 23 of 82 
Final Protocol Version 2.0: 17 November  2021  
 1.2 Trial  Diagram  
Figure 1: Trial Diagram  
Cohort 1 and Cohort 2 can be conducted in parallel.  
Cohort 1:  
Abbreviations: BID, twice daily; OLE, open -label extension.  
Cohort 2: 
Notes: For Cohort 2 only, s creening and skin sample s collection on Day 1 can be performed on the same day  at the 
investigator’s discretion, if no medication washout is required  and the lifestyle considerations are fulfilled . The 
optional follow -up period will occur [ADDRESS_209646], 30 days after the 
screening visit.  For Cohort 2 only (healthy subjects), t he sample collection s on Day 1 can be 
performed on the same day as the screening visit or on separate visit s as per the schedule of events, 
at the investigator’s discret ion. 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 24 of 82 
Final Protocol Version 2.0: [ADDRESS_209647] be 
performed before the IMP application  for subjects in Cohort 1 . If assessments are scheduled for 
the same nominal time, then the assessments should occur in the following order:  
•Patient -reported outcomes
•Investigator assessments
•Vital signs
•Medical photographs
•Collection of s kin sample s
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228   Page 25 of 82  
Final  Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Table 1: Schedule of Events  for Cohort 1 (Subject s with FFA)  
Trial  Visits  Screening  Treatment Period  Follow -
Up ET 
Vehicle -Controlled  OLE  
Day 1  Week 4  Week 8  Week 12  Week 16  Week 20  Week 24  Week 26  - 
V1 V2 V3 V4 V5 V6 V7 V8 V9 - 
Window (days)  -30 to -1 - 2 2 2 4 4 4 4 - 
Informed consent  X          
Demographics  X          
Medical and surgical history  X X         
Inclusion -exclusion  criteria  X X         
Pregnancy testa X X X X X X X X X X 
Clinical laboratory tests 
(biochemistry and hematology)  X X X X X X X X  X 
TSH  and reflex free T4  X          
Serology ( HBV [HBsAg, 
anti-HBc], HCV, HIV)  X          
Electrocardiogram  X          
Complete Physical examination  X    X   X X X 
Brief Physical examination   X X X  X X    
Vital signsb X X X X X X X X X X 
Identification of a lesional target 
area on the scalp and of a non 
lesional  area (eg. occipi[INVESTIGATOR_178382])c X X       
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228   Page 26 of 82  
Final  Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Trial  Visits  Screening  Treatment Period  Follow -
Up ET 
Vehicle -Controlled  OLE  
Day 1  Week 4  Week 8  Week 12  Week 16  Week 20  Week 24  Week 26  - 
V1 V2 V3 V4 V5 V6 V7 V8 V9 - 
Window (days)  -30 to -1 - 2 2 2 4 4 4 4 - 
Perifollicular erythema and scale 
evaluation of the lesional target 
area X X X X X X X X  X 
Pruritus NRSd X X X X X X X X  X 
Burning Sensation NRSd X X X X X X X X  X 
Pain NRSd X X X X X X X X  X 
LPPAI  X X X X X X X  X 
FFASS   X X X X X X X  X 
Hair counts/ Trichoscopy   X   X   X  X 
Hair line measurementse   X   X   X  X 
Medical photographsf  X   X   X  X 
Randomization   X         
IMP application at site  X X X X X X    
IMP application BIDg  X------------------------------------------------------------------------------- X   
IMP distribution   X X X X X X    
IMP collection  and/or 
accountability and/or compliance    X X X X X X  X 
Subject diary 
distribution/collection/review  X X X X X X X X  X 
Local tolerability assessmentsh  X X X X X X X  X 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228   Page 27 of 82  
Final  Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Trial  Visits  Screening  Treatment Period  Follow -
Up ET 
Vehicle -Controlled  OLE  
Day 1  Week 4  Week 8  Week 12  Week 16  Week 20  Week 24  Week 26  - 
V1 V2 V3 V4 V5 V6 V7 V8 V9 - 
Window (days)  -30 to -1 - 2 2 2 4 4 4 4 - 
Skin biopsies collectioni,j  X   X      
Adhesive skin tape strip samplesk  X   X      
Skin microbiome samplesl  X   X      
Concomitant medication  X X X X X X X X X X 
Adverse events collection  X X X X X X X X X X 
Abbreviations: anti-HBc, antibody to hepatitis B core antigen ; BID, twice daily; ET, early termination; FFA, frontal fibrosing alopecia; FFASS, Frontal Fibrosing 
Alopecia Severity Score; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen ; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IMP, 
investig ational medicinal product; LPPAI, lichen planopi[INVESTIGATOR_178387]; NRS, Numerical Rating Scale; OLE, open -label extension; TSH, thyroid -stimulating 
hormone; V, visit.  
a For female  subjects  of childbearing potential , serum pregnancy test at screening and  urine pregnancy test at other specified visits.  
b Including height and weight. Height will be measured only at screening.  
c The lesional target area should  be treated with the IMP  and should be approximately 3 cm x 6 cm (or equivalent). However , a smaller lesional target are a can 
be selected if tape strip pi[INVESTIGATOR_178388]/hair counts is performed or if sample is collected  adjacent/ close  to the lesional 
target area (refer to Section 8.3.2  for details) . If needed, two small lesional target area s (totalling approximately the same size ) could be selected to allow for 
skin samples collection.  
d Subjects will complete their  NRS at home on a daily basis starting approximately [ADDRESS_209648] IMP application. After Day 8 , the NRS will be c ompleted at the site at the specified visits  only.  
e Hair line measurements of lateral canthus (right and left ) to hairline, lower glabellar crease to hair line, top of frontalis muscle to hair line, and mid brow to hair 
line (right and left ). 
f Medical photographs of the target area and the entire scalp (including the frontal hair line and right and left hair line areas).  
g The morning application will be on site on visit days. Other IMP applications will be done at home. The first application of the OLE (delgocitinib cream  
20 mg/g ) is on the morning of Week 12, after all efficacy assessments and skin sample collections are completed. The last application of the OLE is the 
evening prior t o the Week [ADDRESS_209649]’s local tolerability assessment will be done before the IMP 
application with a recall period  of 7 days  (worst over the last 7 days) .  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228   Page 28 of 82  
Final  Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Trial  Visits  Screening  Treatment Period  Follow -
Up ET 
Vehicle -Controlled  OLE  
Day 1  Week 4  Week 8  Week 12  Week 16  Week 20  Week 24  Week 26  - 
V1 V2 V3 V4 V5 V6 V7 V8 V9 - 
Window (days)  -30 to -1 - 2 2 2 4 4 4 4 - 
i On Day 1, 2 skin biopsies ( 4-mm) will be collected prior to the first IMP application (1 from a lesional hair follicle within the target area and 1 from a non 
lesional hair follicle [eg, on the occipi[INVESTIGATOR_178382]]).  On Week 12, 1 skin biopsy ( 4-mm) will be collected from a hair follicle  within the lesional target area (outside 
the scar of previous biops ies).  
j Within 1 0 to 14 days after biopsy collection, suture may be removed, if needed . An additional visit(s) may be necessary  for suture removal only, if suture 
removal is needed after Day  1 and/or Week 12.  
k On Day 1, optional skin tape strips will be collected prior to the first IMP application from lesional skin and from non lesional skin ( eg, on the occipi[INVESTIGATOR_178382] ). 
The lesional skin tape strip should ideally be collected from  the target area but can also be collected adjacent/ close to the target area, as long as it includes a 
portion of lesional skin and is treated with the IMP. On Week 12, skin strips will be collected at the same location of the lesional skin . Every effort s hould be 
made to collect tape strip samples in all subjects however, adhesive tape strip collection is optional and will be collected per investigator judgement (based on 
available skin area  on the scalp ). 
l On Day 1, skin swab for microbiome analysis  will be collected prior to the first IMP application (1 from the target area [lesional skin] and 1 from an uninvolved 
occipi[INVESTIGATOR_178383]) . On Week 12, skin microbiome will be collected at the same  location of the  lesional skin of the  target area .  
 
 
 
 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228   Page 29 of 82  
Final  Protocol Version 2.0: 17 November  2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Table 2: Schedule of Events  for Cohort 2 (Healthy Subjects)  
Trial  Visits  Screening  Sample Collection Day  Follow -Up (Optional)  
V1 V2 V3 
Window (days)  -30 to -1 - 10 to 14 days after Day 1  
Informed consent  X   
Demographics  X   
Medical and surgical history  X X  
Inclusion -exclusion  criteria  X X  
Brief physical examination  X X  
Vital signsa X X  
Skin biopsies collectionb  X  
Suture removal (if applicable)    X 
Adhesive skin tape strip samplesc  X  
Skin microbiome samplesd  X  
Concomitant medication  X X X 
Procedural complications  evaluation  X X X 
Abbreviation: V, visit.  
Note: Screening and Day 1 can be performed on the same day (if subjects do not have a washout period for any of the medications or procedures listed in the 
exclusion criterion  or lifestyle considerations ) and the scheduled assessments on these two days can be completed only once in this case . 
a Including height and weight. Height will be measured only at screening.  
b Two skin biopsies ( 4-mm) that include hair follicles will be collected on healthy skin at similar matched areas of subjects with FFA (ie., 1 from frontal area and 
1 from occipi[INVESTIGATOR_307] s calp area ).   
c Skin tape strips will be collected on non-hair bearing healthy skin at a similar matched area of subjects with FFA (ie, on the forehead, as close as possible to the  
frontal scalp area).  
d Two skin swab samples for microbiome analysis  will be collected on healthy skin at similar matched areas of subjects with FFA (ie, 1 on frontal scalp area  and 
1 from occipi[INVESTIGATOR_178383]) .  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 30 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  2 INTRODUCTION  
2.1  Background  
 Frontal Fibrosing Alopecia  
Frontal fibrosing alop ecia (FFA) was first described in 1994 and is a type of primary lymphocytic 
cicatricial alopecia that is often considered a clinical variant of lichen planopi[INVESTIGATOR_22785] (LPP) due to 
their shared histopathologic features.[ADDRESS_209650] commonly found in 
postmenopausal women  and is increasing in prevalence .3 FFA is characterized by [CONTACT_178433], temporal, or frontotemporal hairline; the clinical pattern is distinct and usually includes 
eyebrow hair loss, as well as other associated symptoms.  Pruritus, facial papules, eyelash loss, 
body hair involvement, and trichodynia may also occ ur in addition to the frontotemporal recession 
and eyebrow loss classically seen.[ADDRESS_209651] treatment regimen for FFA .2 Intralesional  corticosteroids may achieve some disease 
stabilization, with  associated adverse effects such as pain and skin atrophy,  and topi[INVESTIGATOR_178389].1 In addition, n o therapeutic interventions selectively target 
cellular or mo lecular key  elements of  FFA pathogenesis .4  
The etiology and pathogenesis  of FFA are not completely understood and remain areas of  active 
investigation. The inflammatory cell infiltrate surrounding lesional hair follicles , namely around  
the bulge and infundibulum, is characterized by [CONTACT_178434]8+ GranzymeB+ cytotoxic T 
cells and  plasmac ytoid dendritic cells (pDC ), with elevated levels of the chemokine receptor 
CXCR3 expression.4 The available evidence suggests a key role for interferon ( IFN)-γ in inducing 
hair follicule immune privilege (HFIP) bulge collapse and subsequent  immune -mediated epi[INVESTIGATOR_178390] (eHFSC ) destruction  observed in FFA .4 Therapeutically, bulge immune 
privilege  protection/restoration or neutralizing  IFN-γ may h elp to better manage this highly  
treatment -resistant cicatricial alopecia .  
 Delgocitinib  
Delgocitinib is a novel pan-Janus kinase (JAK) inhibitor.  After a cytokine binds to its receptor, the 
JAK family is  activated intracellularly, and promotes growth and activation of a variety of cells 
(eg, lymphocytes) via phosphorylation of the downstream substrate signal transducer and activator  
of transcription (STAT) . The JAK family is essential for the physiological activity of cytokines 
and plays a criti cal role in the pathogenesis of diseases with an immunoinflammatory component.[ADDRESS_209652] is a promising target for the treatment of disorders with an  
immunoin flammatory component.  Several JAK inhibitors (such as ruxolitinib, baricitinib, and 
tofacitinib) are in clinical  development or are already approved for oral or topi[INVESTIGATOR_178391] . Delgocitinib ointment  (that was developed by [CONTACT_178435].  [JT]) has been approved for topi[INVESTIGATOR_178392] 2 years and older and 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 31 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  adults with atopic dermatitis  (AD)  in Japan  and d elgocitinib cream  has shown promising efficacy 
in inflammatory skin diseases suc h as chronic hand eczema and AD.5  
Based on the nonclinical and clinical data currently available, delgocitinib has the potential to  
become a novel local -acting, selective  immunosuppressive agent suitable for the topi[INVESTIGATOR_178393].5 
 Trial Rationale  
FFA demonstrated significant upregulation of T helper 1/IFN  (IFN -γ, CXCL9/CXCL10), the 
JAK-STAT pathway (STAT1, JAK3) and fibrosis -related products  (vimentin, fibronectin ).1 The 
increased expression of IFN -γ-inducible chemokines (CXCL9, CXC10, and CXC11) and cognate 
receptor 3 (CX CR3) in lesional FFA bulge epi[INVESTIGATOR_178394]9/10/[ADDRESS_209653] may be a novel approach to suppress aberrant immune 
responses in patients with FFA.6  
It is hypothesized that delgocitinib cream 20 mg/g will reduce INF -γ driven inflammation in 
subjects with FFA . In the present trial, the molecula r signature [CONTACT_178485][INVESTIGATOR_178395] 20 mg/g in subjects with FFA  will be evaluated. The safety and 
preliminary efficacy  of delgocitinib cream in subjects with FFA  will also be evaluated.  
2.2  Risk/Benefit Assessment  
 Known Po tential Risks  
A total of 15 clinical trials, 1 with oral delgocitinib  (sponsored by [CONTACT_140521]) , 11 with delgocitinib 
ointment  (7 sponsored by [CONTACT_178436] 4 sponsored by [CONTACT_82102] A/S) , and 3 with  delgocitinib cream  
(sponsored by [CONTACT_73313]  A/S) , have been completed  and 2 clinical trials with delgocitinib cream 
are currently ongoing  (sponsored by [CONTACT_73313]  A/S) . In total, 54 subjects were dosed orally 
with delgocitinib (at doses between 1 and 100 mg) and  1635 subjects were exposed topi[INVESTIGATOR_178396] (1165 subjects at  concentrations between 0.3 and 30 mg/g) or delgocitinib 
cream (470 subjects at concentrations between 1 and  20 mg/g).  
Delgocitinib ointment and delgocitinib cream were well tolerated in the conducted clinical  trials  
and systemic exposure to delgocitinib has been low . No clinical indication of any phototoxic 
potential was observed for delgocitinib cream when  single occlusive application of delgocitinib 
was followed by [CONTACT_178437].  Potential risks to humans that could arise from 
use of delgocitinib cream are local skin  infection, and acneiform eruptions, which have been 
reported in clinical trials with  delgocitinib ointment. Only few serious adverse events ( SAEs ) were 
reported in the completed clinical  trials. Except for one, all SAEs were considered not related to 
treatment. There was no pattern in  the reported preferred terms  (PT). The one related SAE was an 
event of Kaposi’s varicelliform eruption  reported in a JT trial with d elgocitinib ointment  in 
Japanese subjects . The subject experiencing this event was hospi[INVESTIGATOR_057], and the event was 
resolved.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 32 of 82 
Final  Protocol Version 2.0: [ADDRESS_209654] values , in systolic blood pressure, 
diastolic blood pressure,  pulse rate, or body temperature were observed in subjects  exposed to 
delgocitinib cream. Lymphocytopenia was observed in oral nonclinical toxicity studies and is 
considered a  potential clinical consequ ence of systemic levels of delgocitinib. Lymphocytopenia 
is therefore considered an important potential risk for delgocitinib cream . 
Further information related to nonclinical and clinical studies is available in the Investigator 
Brochure  (IB).[ADDRESS_209655] ( IMP) during the vehicle --controlled treatment period and all subjects continuing into the 
OLE will see an improvement or a stabilization in their FFA condition as a result of participating 
in this Phase 2a trial. 
For Cohort 2, t here are no anticipated benefits for subjects participating in t he trial, other than the 
benefit of medical evaluation at screening and throughout the trial. 
Participation in this trial may help generate future benefit for larger groups of patients with FFA.  
 Assessment of Risks and Benefits  
All previous data demonstrat ed in nonclinical and clinical trials  are considered sufficient to expect 
a positive benefit/risk ratio for the treatment of FFA with delgocitinib cream  20 mg/g , and therefore 
to initiate this trial. 
The risk s to subjects in this trial will be minimized by  [CONTACT_178438], 
proper trial design, and close monitoring.  
 COVID -19 Pandemic  
Initiating and conducting clinical trials during Coronavirus Disease 2019  (COVID -19) pandemic,  
presents numerous challenges . Control measures in place in different regions may impact the 
ability to adhere  to some of the trial procedures described in this protocol. Due  to challenges that 
include but are  not limited to participant preferences, site closures, travel restrictions, and 
quarantines, some  modifications to trial conduct during the COVID -19 pandemic may be 
necessary to ensure  trial continuity  and safety of the participants and trial staff.  Adequate 
benefit/risk analyses should be applied relative to the completion of study procedures.  Recog nizing 
the flexibility required to manage the impact of the pandemic on this clinical trial, additional details 
may be added to study manual(s)  and communicated to the site , as needed.   
Taking into account the modifications to trial conduct that could occ ur to minimize risk related to 
COVID -19 in this trial, the potential risks to participate in this trial during the pandemic are 
justified by [CONTACT_178439]. 
In addition, i t is not believed that treatment with delgocitinib cream will put subjects at an 
increased risk for viral infections, including SARS -CoV -2. Vaccination for COVID -19 will be 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 33 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  allowed during the study, if needed , without changes in currently planned trial procedures and IMP 
application s.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 34 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  3 OBJECTIVE S AND ENDPOINTS  
OBJECTIVES  ENDPOINTS  
Primary   
To assess molecular 
signature [CONTACT_178488][INVESTIGATOR_178397] 20 mg/g in subjects 
with FFA  Primary endpoint:  
• Change in expression of CXCL9, CXCL10 , and IFN-γ from 
baseline to Week 12 . 
Secondary   
To evaluate the safety and 
tolerability of delgocitinib 
cream 20  mg/g following 
topi[INVESTIGATOR_178398] -controlled 
treatment period . Safety endpoint during the vehicle -controlled treatment period:  
• Number of TEAEs  from baseline to Week  12.  
 
Exploratory   
To evaluate the safety and 
tolerability of delgocitinib 
cream 20 mg/g during the 
OLE.  Exploratory safety  endpoint : 
• Number of TEAEs during the OLE  (up to Week 26)  
To evaluate the 
preliminary efficacy of 
delgocitinib cream 
20 mg/g following topi[INVESTIGATOR_178399].  Exploratory e fficacy endpoints during the vehicle -controlled 
treatment period:  
• Change in LPPAI score from baseline to Weeks 4, 8, and 12.  
• Change in FFASS  score from baseline to Weeks 4, 8, and 12.  
• Change in target area perifollicular erythema score from 
baseline to Weeks 4, 8, and 12.  
• Change in target area perifollicular scale score from baseline 
to Weeks 4, 8 , and 12.  
• Change in pruritus NRS score from baseline to Days 2, 3, 4, 
5, 6, 7, 8, and Weeks 4, 8, and 12.  
• Change in burning sensation NRS score from baseline to 
Days 2, 3, 4, 5, 6, 7, 8, and Weeks 4, 8, and 12.  
• Change in pain NRS score from baseline to Days 2, 3, 4, 5, 
6, 7, 8, and Weeks 4, 8, and 12.  
• Proportion of subjects with a 3 -point reduction * in pruritus 
NRS score from baseline to Days 2, 3, 4, 5, 6, 7, 8, and 
Weeks  4, 8, and 12.  
• Proportion of subjects with a 4 -point reduction * in pruritus 
NRS score from baseline to Days 2, 3, 4, 5, 6, 7, 8, and 
Weeks  4, 8, and 12.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 35 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  OBJECTIVES  ENDPOINTS  
• Proportion of subjects with a 3 -point reduction * in burning 
sensation NRS score from baseline to Days 2, 3, 4, 5, 6, 7, 8, 
and Weeks 4, 8, and 12.  
• Proportion of subjects with a 4-point reduction * in burning 
sensation NRS score from baseline to Days 2, 3, 4, 5, 6, 7, 8, 
and Weeks 4, 8, and 12.  
• Proportion of subjects with a 3 -point reduction * in pain NRS 
score from baseline to Days 2, 3, 4, 5, 6, 7, 8, and Weeks 4, 
8, and 12.  
• Propo rtion of subjects with a 4 -point reduction * in pain NRS 
score from baseline to Days 2, 3, 4, 5, 6, 7, 8, and Weeks 4, 
8, and 12.  
• Change in target area hair counts/trichoscopy via fotofinder 
trichovision from baseline to Week  12. 
Exploratory e fficacy endpoints during the OLE:  
• These efficacy outcomes will be measured at scheduled visits 
after Week 12: LPPAI, FFASS, target area perifollicular 
scale score, target area perifollicular erythema score, pruritus 
NRS, burning sensation NRS, pain NRS, and target area hair 
counts/trichoscopy via fotofinder trichovision.  
Abbreviations: CXCL9, chemokine (C -X-C motif) ligand 9 ; 10, chemokine (C -X-C motif) ligand 10; 
FFA,  frontal fibrosing alopecia; FFASS, Frontal Fibrosing Alopecia Severity Score; INF, interferon , 
LPPAI,  Lichen Planopi[INVESTIGATOR_178370]; NRS, Numerical Rating Scale; TEAE, treatment -emergent adverse 
event . 
* Only subjects with a baseline NRS score ≥3 will be included in the respective endpoints on proportion of 
subjects with a 3 -point reduction. Only subjects with a baseline NRS score ≥4 will be included in the respective 
endpoints on proportion of subjects w ith a 4 -point reduction.  
 
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 36 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  4 TRIAL  DESIGN  
4.1  Overall Design  
A Phase 2a, randomized, double -blind, vehicle -controlled, single -site, exploratory trial  of 
delgocitinib cream 20 mg/g in subjects with FFA.  
The trial will consist of 2 cohorts: Cohort 1 will include approximately 30 subjects with FFA and 
Cohort  2 will include approximately 5 healthy postmenopausal female subjects. Both cohorts can 
be conducted in parallel.  
Cohort 1:  
All subjects will read and sign an informed consent form  (ICF)  prior to any trial-related activities  
being performed. Subjects who fulfill all of the inclusion criteria and none of the exclusion criteria 
will be randomized  into the trial. After a screening period of no more than 30 days (fr om Day -30 
to Day  -1), eligible subjects will be randomized (1:1) on Day 1 to apply delgocitinib cream 20 mg/g  
or vehicle cream BID for 12 weeks during the vehicle -controlled treatment period. All subjects 
who complete the vehicle -controlled treatment peri od will then continue into the OLE and apply 
delgocitinib cream 20 mg/g  BID for 12 weeks. The OLE period will be followed by a 2 -week 
safety follow -up period. For scheduled trial visits, subjects will come to the site on 9 occasions: 
screening, Day 1, Week  4, Week 8, Week 12, Week 16, Week 20, Week 24, and Week 26/early 
termination (ET).   
On Day 1, a lesional target area on the scalp (eg, frontal, periauricular , or temporal area) that be 
treated with the IMP  will be identifi ed. To allow for the hair count/trichoscopy assessment and all 
samples collection ( ie, skin biopsies, tape strippi[INVESTIGATOR_007], and skin swabs) the lesional target area should 
be approximately 3 cm x 6 cm (or equivalent). However, as tape strips can be collected fro m the 
same area where trichoscopy/hair counts is performed or can be collected adjacent /close  to the 
lesional  target area (refer to Section 8.3.2  for details), a smaller lesional target area may be 
acceptable. I f needed , two small target areas (totalling approximately the same size) could also be 
selected to allow for skin samples colle ction  and hair count/trichoscopy assessment. If two lesional 
target areas are selected, they should be of similar severity.    
The following skin samples will be collected during the trial to assess molecular signature [CONTACT_178486]:  
- Skin biopsies for transcriptomic and immunohistochemistry (IHC)  analys es (n=3):  
o Day 1:  2 skin biopsies ( 4-mm) will be collected prior to the first IMP application 
(1 from a lesional hair follicle within the target ar ea and 1 from a non lesional hair 
follicle [eg, on the occipi[INVESTIGATOR_178382]]).  
o Week 12:  1 skin biopsy ( 4-mm) will be collected from a hair follicle within the 
lesional target area (outside the scar of previous biopsies).  
- Skin swabs for microbiome  analysis (n=3) : 
o Day 1 : [ADDRESS_209656] IMP 
application (1  from the target area [lesional skin] and 1 from an uninvolved 
occipi[INVESTIGATOR_178383]).  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 37 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  o Week 12 : 1 skin microbiome sample will be collected at the same location of the  
lesional skin of the  target area.  
- Adhesive tape strips samples for transcriptomic analysis (n= 3): 
o Day 1 : skin tape strips will be collected prior to the first IMP application from 
lesional skin and from a nonlesional skin (eg, on the occipi[INVESTIGATOR_178382]) . 
o Week 12 : skin tape strips will be collected at the same location of the lesional skin .  
Note:  Every effort should be made to collect tape strip samples in all subjects however, 
adhesive tape strip collection is optional and will be collected per investigator ’s 
judgement (based on available skin area  on the scalp ). 
Safety will be assessed by [CONTACT_178431] (AEs), recording vital signs, performing 
complete and brief physical examinations, and evaluating clinical laboratory results and local 
tolerability assessments (LTA).  
Efficacy will be assessed using LPPAI,  FFASS,  evaluation of the perifollicular er ythema and 
perifollicular scale, pruritus NRS, burning sensation NRS, pain NRS, and hair  counts/trichoscopy 
(eg, number of hairs, hair diameter, and hair density). Hair line measurements ( ie, lateral canthus 
[right and left] to hairline, lower glabellar cr ease to hair line, top of frontalis muscle to hair line, 
and mid brow to hair line [right and left]) will also be done.  
Medical photographs of the lesional target area and the entire scalp (including the frontal hair line 
and right and left hair line areas ) will be taken with the fotofinder device during the trial. 
Cohort 2:  
All subjects will read and sign an ICF prior to any trial-related activities  being performed. Subjects 
who fulfill all of the inclusion criteria and none of the exclusion criteria will be accepted into the 
trial. After a screening period of no more than 30 days (from Day -30 to Day -1), eligible subjects 
will be asked to come at t he site for skin samples collection. Screening and skin samples collection 
on Day 1 can be performed on the same day (if subjects do not have a washout period) or on two 
separate visits, at the investigator’s discretion.  No investigational product will be administered in 
Cohort 2.  For scheduled trial visits, subjects will come to the site on up to 3 occasions: screening, 
Day 1, and optional follow -up visit.  
The following skin samples will be collected:  
- Skin biopsies (n=2):  
o Day 1:  2 skin biopsies ( 4-mm) that  include hair follicles will be collected on healthy 
skin at similar matched areas of subjects with FFA (ie, 1 from frontal scalp area 
and 1  from occipi[INVESTIGATOR_178383])  
- Adhesive tape strips (n=1):  
o Day 1 : skin tape strips will be collected on non -hair bearin g healthy skin at a similar 
matched area of subjects with FFA (ie, on the forehead, as close as possible to the 
frontal scalp area).  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 38 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  - Skin swabs for microbiome  analysis (n=2):  
o Day 1 : 2 skin microbiome samples will be collected on healthy skin at similar 
matched areas of subjects with FFA (ie, 1 from frontal scalp area and 1 from 
occipi[INVESTIGATOR_178383]).  
For Cohort [ADDRESS_209657] of delgocitinib cream 20 mg/g on the molecular 
signature [CONTACT_178489].  Frontal fibrosing alopecia  demonstrated significant upregulation of 
T helper 1/IFN (IFN -γ, CXCL9/CXCL10), the JAK -STAT pathway (STAT1, JAK3) and 
fibrosis -related products (vimentin, fibronectin) . Delgocitinib is a novel pan - JAK inhibitor. It is 
hypothesized that delgocitinib cream  20 mg/g will reduce INF -γ driven inflammation in subjects 
with FFA.  The proposed design is considered appropriate for assessing the molecular signature  
[CONTACT_178486] , the safety , as well as preliminary efficacy  of delgocitinib cream 20 mg/g in subjects with 
FFA.  
In this Phase 2a trial, the vehicle -controlled treatment period will be randomized to ensure random 
allocation of subjects to treatment arms to reduce bias. Because efficacy assessments of FFA have 
a high degree of subjectivity, the trial will be double -blinded. The highest degree of patient and 
assessor blinding should be sought to achieve credible inference. It is also important to have a 
vehicle control in the Phase 2a trial to control for confounding factors, such as potential 
investigator bias, and to ensure that the statistical procedures can be appropriately applied.  After 
completion of the vehicle -controlled treatment period , all subjects will have the opportunity to 
continue into the OLE and to receive the active drug for a period of [ADDRESS_209658] skin samples will allow 
comparison of the molecular and cellular fingerprint to that of subjects with FFA.  
4.3  Justification for Dose  
The justification for the delgocitinib dose is based on the findings from the Phase 2b trial in 
subjects with AD. Delgocitinib cream was tested at 4 different strengths (1, 3, 8 , and 20 mg/g) 
BID for up to 8 weeks in subjects with AD. A statistically signi ficant dose -response was 
established for the primary endpoint (change in Eczema Area and Severity Index  [EASI ] from 
baseline to Week 8), and the secondary endpoints ( Validated Investigator Global Assessment for 
Atopic Dermatitis  treatment success [ vIGA -AD TS] at Week 8 and EASI75 [a 75 % reduction in 
EASI  score ] at Week 8).  The highest treatment effect (compared to cream vehicle) was seen with 
delgocitinib cream 20  mg/g.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 39 of 82 
Final  Protocol Version 2.0: [ADDRESS_209659] scheduled procedure shown in the Schedule of Events,  
Table 1 (for Cohort 1) and  Table 2 (for Cohort 2) . 
The end of the trial is defined as completion of the last visit or procedure shown in the schedule of 
event for th e last enrolled subjec t in Cohort 1 and Cohort 2 .  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 40 of 82 
Final  Protocol Version 2.0: [ADDRESS_209660] meet all of the following criteria , 
either  at the screening and Day 1  visits  or only at one of the specified visits (screening or Day 1) 
as noted in the criterion :  
Inclusion criteria for all subjects:  
1. Subject is willing to participate and is capable  of giving informed consent. Note: Consent must 
be obtained prior to any trial-related procedures.  
2. Subjects must be willing to comply with all trial procedures and must be available for the 
duration of the trial. 
Inclusion criteria for Cohort 1 only (subjects with FFA):  
3. Male or female subject aged [ADDRESS_209661] has clinically confirmed diagnosis of FFA based on investigator’ s judgment.  
6. Subject has a target area with a perifollicular erythema score ≥ 2 and a perifollicular scale score 
≥ [ADDRESS_209662] who uses make -up, moisturizers, creams, lotions, cleansers, and/or sunscreens  on 
the face, subject has used the same product brands/types for a minimum period of 4 weeks 
prior to Day 1, agrees not to change brand/type or frequency of use throughout the trial, agrees 
not to apply those products on the treated area during the trial, and agrees not  to use make -up, 
moisturizers, creams, lotions, cleansers, and/or sunscreens on the face on the clinic visit days 
before the visit.  
8. Subject is willing to maintain a consistent hair style and hair style regimen, including shampoo 
and hair products (includin g hair dye, process, and timing to hair appointments), and to refrain 
from weaves or extensions throughout the course of the trial and for 4 weeks prior to Day 1.  
Note: Hair dying and shaving of scalp is allowed during the trial but not within [ADDRESS_209663] of childbearing potential involved in any sexual intercourse that could lead 
to pregnancy: the subject must agree to use an effective contraceptive method from at least 
[ADDRESS_209664] IMP application . Effective 
contraceptive methods include hormonal contraceptives (eg, combined oral contraceptive, 
progesteron e-only hormonal contraception [associated with or without inhibition of ovulation  
as the primary mode of action ], patch, vaginal ring, injectable, or implant), intrauterine devices 
or intrauterine systems, vasectomized partner(s) (provided his vasectomy was performed 
≥4 months prior to Screening) , tubal ligation or a barrier method of contraception (eg, male 
condom, female condom, cervical cap, diaphragm, contraceptive sponge) in conjunction with 
spermicide.  
Note: Subjects must have been on a stable dose of hormonal contraceptives for at least 4 weeks 
before Day 1.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 41 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Note: The above list of contraceptive metho ds does not apply to subjects who are abstinent for 
at least [ADDRESS_209665]. Periodic 
abstinence (calendar, symptothermal, post -ovulation methods) is not acceptable.  
Note:  A female subject of nonchildbearing potential is defined as follows:  
– Female subjec t who has had surgical sterilization (hysterectomy, bilateral oophorectomy, 
or bilateral salpi[INVESTIGATOR_1656])  
– Female subject who has had a cessation of menses for at least 12 months prior to the 
screening visit without an alternative medical cause  
Inclusion cri teria for Cohort 2 only (healthy subjects):  
10. Female subject aged 45 years of age or older at the time of consent.  
11. Female is postmenopausal as defined below:  
– Female subject who has had surgical sterilization (hysterectomy, bilateral oophorectomy, 
or bilateral salpi[INVESTIGATOR_1656])  
– Female subject who has had a cessation of menses for at least [ADDRESS_209666] is in good general health, according to the investigator’s judgment  based on vital signs , 
medical history , and brief physical examination .  
5.[ADDRESS_209667] who meets any of the following criteria at the screening and /or Day 1  visits, as 
applicable , will be excluded from participation in this trial: 
Exclusion criteria for all subjects:  
1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant 
during the trial. 
2. Subject has received any marketed or investigational biolo gical agent within 12 weeks or 
5 half-lives (whichever is longer) prior to Day 1.  
3. Subject is currently receiving a nonbiological investigational product or device or has received 
one within [ADDRESS_209668] has had excessive sun exposure or has used tanning booths within 4 weeks prior to 
Day 1 or is not willing to minimize natural and artificial sunlight exposure during the trial. Use 
of sunscreen products (except on treated areas for subjects in Cohort  1) and protective apparel 
are recommend ed when sun exposure cannot be avoided.  
5. Subject has a history of an allergic reaction or significant sensitivity to lidocaine or other local 
anesthetics.  
6. Subject has a history of hypertrophic scarring or keloid formation in scars or suture sites.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 42 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Exclusion  criteria for Cohort 1 only (subjects with FFA):  
7. History of other scalp/hair disease including discoid lupus erythematosus and central 
centrifugal cicatricial alopecia.  
Note: Subjects with lichen planopi[INVESTIGATOR_22785] /FFA overlap are not to be excluded.  
8. Presence of active dermatologic condition that might interf ere with FFA diagnosis and/or 
interfere with the trial assessments  such as seborrheic dermatitis, psoriasis, or telogen 
effluvium.  
9. Subject who has undergone scalp reduction surgery or hair transplantation.  
10. Use of adhesive wigs during the trial. 
11. Subject is known to have immune deficiency or is immunocompromised.  
12. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. 
Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal cell 
carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.  
13. Subject had a major surgery within [ADDRESS_209669] has uncontrolled hypo - or hyper thyroidism or has both thyroid -stimul ating hormone 
(TSH ) and free T4 levels  outside normal range  at screening .  
15. Subject has any clinically significant medical condition or physical/laboratory/ ECG/ vital signs 
abnormality that would, in the opi[INVESTIGATOR_871], put the subject at undue risk or 
interfere with interpretation of trial results.  
16. Subject has positive results for hepatitis B surface antigens (HBsAg), antibodies to hepatitis B 
core antigens (anti -HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).  
17. Subject has used treatment with agents (including natural products or nutritional supplement  
such as Viviscal , Nutrafol, and/or biotin ) that may affect hair regrowth in the last [ADDRESS_209670] has used systemic treatment with immunosuppressive/modulating medication or 
medication that could affect FFA (eg, corticosteroids, methotrexate, minoxidil, 
hydroxychloroquine, retinoids, calc ineurin inhibitor, tetracyclines, pi[INVESTIGATOR_051], 
spi[INVESTIGATOR_8407], or 5 -α-reductase -inhibitors)  within 4 weeks prior to Day  1.  
Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops 
containing corticosteroids are also all owed.  
Note: Standard doses of s ystemic antihistamines are allowed.  
Note: Use of systemic treatment with minoxidil or spi[INVESTIGATOR_178400] 
[ADDRESS_209671] FFA within 2  weeks prior 
to Day  1, including, but not limited to, topi[INVESTIGATOR_11930], calcineurin inhibitors, minoxidil, 
phosphodiesterase -4 (PDE -4) inhibito rs. 
Note: Use of topi[INVESTIGATOR_178385] [ADDRESS_209672] agrees to continue using it on a stable dosing during the present study.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 43 of 82 
Final  Protocol Version 2.0: [ADDRESS_209673] has received treatment with JAK inhibitors (systemic or topi[INVESTIGATOR_2855]) within [ADDRESS_209674] has received any ultraviolet (UV) -B phototherapy (including tanning beds), excimer 
laser, or any other phototherapy within [ADDRESS_209675] has had psoralen -UV-A (PUVA) treatment within [ADDRESS_209676] year prior 
to Day 1.  
Exclusion criteria for Cohort 2 only (healthy subjects):  
27. Subject has a history of skin disease or presence of skin condition that, in the opi[INVESTIGATOR_1070], would interfer e with the trial assessments.  
28. Subject has any clinically significant medical condition or physical/ vital signs abnormality that 
would, in the opi[INVESTIGATOR_871], put the subject at undue risk or interfere with 
interpretation of trial results.  
29. Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or 
HIV).  
30. Subject has used a topi[INVESTIGATOR_178386] 2 week s prior 
to skin samples collection (Day 1).   
5.3  Lifestyle Considerations  
Cohort 1:  
For subject who uses make -up, moisturizers, creams, lotions, cleansers, and/or sunscreens  on the 
face, the same product brands/types should be used for a minimum period of [ADDRESS_209677] should continue to use the same brand/type or frequency of use throughout the trial , 
but should not apply those products on the treated area during the trial .  On clinic visit days, 
subjects should  not use make -up, moisturizer s, creams, lotions, cleansers, and/or sunscreens on the 
face on the clinic visit days before the visit . In addition, for the subjects who are on stable dose of 
topi[INVESTIGATOR_178401] [ADDRESS_209678] should  maintain a consistent hair style and hair style regimen, including shampoo and hair 
products (including hair dye, process, and timing to hair appointments), and should refrain from 
weaves or extensions throughout the course of the trial  and for 4 weeks pr ior to Day 1.  Hair dying 
and shaving of scalp is allowed during the trial but not within 48 hours prior to a trial visit. Subjects 
will be informed to wash their scalp/hair approximately 48 hours prior the visits on Day 1 and 
Week 12 and then to keep their  hair free of products until these visits (ie , the visits where skin 
microbiome will be collected). For other visits (Weeks 4, 8, and 24  [or ET, as applicable] ), subjects 
will be informed that they should not apply hair products before the visits.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 44 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  The IMP should be applied after hair washing if this coincides with time for IMP application. 
Subjects should abstain from wetting the hair and eyebrows (if eyebrows are treated ) within 
[ADDRESS_209679] 30 minu tes after IMP 
application to wear protective apparel (eg, hat) or non-adhesive hair pi[INVESTIGATOR_13959]/wig that cover treated 
areas.  
Subjects should abstain from physical activity that can cause significant sweating within [ADDRESS_209680] with the IMPs. 
Cohort 2: 
On the Day 1 visit , subjects should  not use make -up, moisturizers, cre ams, lotions, cleansers, 
and/or sunscreens on the face before the visit .  
Subjects will be informed to wash their scalp/hair approximately 48 hours prior to the Day 1 visit 
and then to keep their hair free of products until the visit.  
5.4  Screen Failures  
Screen failures are defined as individuals who consent to participate in the clinical trial but  are not 
subsequently randomly assigned to the IMP. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure subjects, to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements, and to respond to queries 
from regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any SAEs.  
Individuals who do not meet the criteria for participation in this trial (screen failure) may be 
rescreened once, if deemed acceptable by [CONTACT_093]. Rescreened subjects should be assigned 
a different subject number than the initial screening.  All procedures planned at the  screening visit , 
including signature [CONTACT_4007] a new consent form, will be performed.  
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 45 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  6 TREATMENT  
6.1  Trial  Treatment Administered  
No IMP will be administered in Cohort 2. For Cohort 1, t he vehicle -controlled treatment period 
involves a compa rison of delgocitinib cream 20 mg/g administered topi[INVESTIGATOR_178402] a vehicle  
(delgocitinib cream vehicle) . During the OLE, all subjects will apply delgocitinib cream 20 mg/g  
BID. All IMPs  will be provided by [CONTACT_456].  
On Day 1, trial staff will instruct subjects on proper application of IMP. On Day 1, Week  4, 
Week  8, Week 12, Week 16, and Week 20, the morning application of the IMP will be at the site 
under the supervision of trial staff. Other IMP applications will be self -administer ed by [CONTACT_178440] . The last IMP application will be the evening prior to the Week 24 visit. No IMP 
application will be done on the day of the Week 24 visit . Typi[INVESTIGATOR_897], dosing will occur in the 
morning and evening, with approximately 12  hours betwee n doses. The IMP will be applied  to all 
affected  areas on the face /scalp  (ie, frontal scalp  area, including the lesional target area,  and 
eyebrows , if affected ) as a thin layer. The original lesional area(s) identified  at Day 1 and any new 
lesions (or increase in original lesional area) on the face /scalp  must be treated until Week [ADDRESS_209681] 30 minutes before covering the treated areas .  
Table 3: Trial  Treatment s 
 Trial  Treatmen ts 
Product name  [CONTACT_178490] d ose 
strength(s)/Dosage level(s)  20 mg/g  NA 
Route of Administration   Topi[INVESTIGATOR_178403]/scalp  (ie, frontal scalp and 
eyebrows , if affected ) for 12 weeks 
during the vehicle -controlled 
treatment period and for 12 weeks 
during the OLE . Applied BID to all  affected areas 
on the face/scalp  (ie, frontal 
scalp and eyebrows , if affected ) 
for [ADDRESS_209682] white cream  Vehicle  is identical to the active 
cream . 
Source of procurement  LEO Pharma A /S LEO Pharma A /S 
Abbreviations:  BID, twice daily; NA , not applicable ; OLE, open -label extension . 
The contents of the label will be in accordance with all applicable regulatory requirements . 
 Treatment Interruption  
In the event of an AE or laboratory abnormality, individual subject trial treatment may be 
temporarily interrupted based on the investigator’s judgment and preferably following a discussion 
with the Medical Monitor.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 46 of 82 
Final  Protocol Version 2.0: [ADDRESS_209683]’s best interest. However, the Medical Monitor sh ould be contact[CONTACT_178441]. Resumption of trial treatment after temporary 
discontinuation should always be discussed with the Medical Monitor.  
The information pertaining to interruption of trial medicatio n and the reasons for it must be 
recorded in the case report form.  
6.2  Preparation/Handling/Storage/Accountability  
 Preparation /Storage/Handling   
All IMPs  must be stored in a secure environmentally controlled and monitored area in accordance 
with the labelled storage conditions with access limited to the investigator and authorized site staff. 
The IMPs  may only be supplied by [CONTACT_178442] [ADDRESS_209684] in Cohort 1 at the 
visits specified in  Table 1. Sub jects are to return all IMPs (used and unused) to the site. The tubes  
will be weighed  prior to dispensing and upon return , and the weight  will be recorded in the source 
documents and electronic case report form  (eCRF ). Each subject will be instructed on the 
importance of returning IMP at the next trial visit and on taking the product as prescribed . If a 
subject does not return IMP, he or she will be instructed to return it as soon as possible . 
More details on the application methods are described in the study manual.  
 Accountability  
The investigator is responsible for maintaining accurate records o f the IMP received initially  and 
of the IMP dispensed/used . Any IMP accidentally or deliberately destroyed, or returned to the 
sponsor or designee will be accounted for. Any discrepancies between amounts dispensed and 
returned will be explained.  At the con clusion of the trial, all used and unused investigational 
products and all medication containers will be returned or destroyed as per approved arrangements 
by [CONTACT_1034] .   
All IMP accountability forms and treatment logs must be retained in the investigator’s study file s. 
Product  inventory and accountability records will be maintained , as per ICH GCP . These records 
must be available for inspection at any time by [CONTACT_456] , its desi gnees , or by [CONTACT_17513].  
Further guidance and information for final disposition of IMPs are provided in the study manual . 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 47 of 82 
Final  Protocol Version 2.0: [ADDRESS_209685] identifier number will contain the site 
number  (ie, 01) and the subject number and will be assigned in numerical order at the screening 
visit based on chronological order of screening dates (e.g., [ADDRESS_209686] screened).  
In Cohort 1, a pproximately 30 subjects will be randomized 1:1 to delgocitinib cream 20 mg/g or 
vehicle  cream .  
Further guidance and information about randomization assignment can be obtained in the study 
manual.  The randomization number is to be recorded at the appropriate location in the source 
document and eCRF.  
In Cohort 2, n o randomization scheme will be used since no IMP will be applied.  
 Blinding 
The vehicle -controlled treatment period of Cohort [ADDRESS_209687] research organization ( CRO ), or the sponsor’s trial team 
until after the co nclusion of the trial. 
While the safety of a subject always comes first, it is still important to carefully consider if 
unblinding is necessary to ensure a subject’s safety. An emergency unblinding request can be made 
by [CONTACT_093], health care profe ssionals who are not members of the trial staff, or authorized 
LEO Pharma personnel.  
Provisions are in place for [ADDRESS_209688] to the emergency unblinding facility  who will 
immediately reveal the individual treatment allocation.  
For a requester who is not a member of the site staff (eg , a physician in an emergency room), the 
local contact [CONTACT_178443]. Like the investigator or 
delegated site staff, the requester need s to provide the trial ID, the subject ID and the randomization  
code number to the emergency unblinding facility , that will immediately reveal the individual 
treatment allocation.  
The emergency unblinding facility  will clarify that the requester requires immediate unblinding 
without  further medical consultation.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 48 of 82 
Final  Protocol Version 2.0: [ADDRESS_209689] to 
continue in the trial. The primary reason for discontinuation (the event or condition which led to 
the unblinding) will be recorded . 
 Trial  Treatment Compliance  
Trial  treatment compliance  will be monitored  at each visit. Adherence to treatment  will be assessed 
by [CONTACT_81257], review of the subject ’s diary , and by [CONTACT_178444]. The date and time of each dose administered in the clinic will be recorded.  
Subject s who are significantly noncompliant  with treatment  will be counseled and could be 
discontinued from the trial, at the discretion of the investigator , following consultation wit h the 
sponsor.  A subject  will also be considered significantly noncompliant if he or she intentionally or 
repeatedly takes more than the prescribed amount of IMP in the same time frame , as judged by [CONTACT_1275].   
6.4  Concomitant Therapy  
All medications (including over -the-counter drugs, vitamins, herbal/natural products, and 
antacids) taken within [ADDRESS_209690] be recorded within the timeframe described 
in the exclusion criteria . 
Medication entries may be captured as generic  or trade  name s. Trade name s should  be used for 
combination drugs. Entries should include as much as possible of the following information: the 
dose, unit, frequency of administration, route of administration,  start date, end date, and indication. 
If the medication is stopped  or the dosage  is changed, these details must be recorded.  
 Permitted Therapi[INVESTIGATOR_178404]:  
• Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye  and ear  drops containing 
corticosteroids are also allowed.   
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 49 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  • Standard doses of s ystemic antihistamines are allowed.  
• Use of systemic treatment with minoxidil or spi[INVESTIGATOR_178400] 
[ADDRESS_209691] agrees to continue using it on a stable dos ing during 
the present study.   
• Use of topi[INVESTIGATOR_178385] [ADDRESS_209692] agrees to continue using it on a stable dosing during the present study.  
• Use of sunscreen products , except on treated  areas , and protective apparel are permitted when 
sun exposure cannot be avoided.  Of note, subjects should wait at least 30 minutes after IMP 
application to wear protective apparel (eg, hat) or non -adhesive hair pi[INVESTIGATOR_13959]/wig that cover 
treated areas.  
• Vaccination for COVID -[ADDRESS_209693] on efficacy assessment or safety of the subjects is expected. If in any doubt, 
investigators are advise d to discuss medications with the medical monitor.    
For subjects in Cohort 2, Table 5 lists prohibited medications that are not to be used from the 
defined washout periods before the Day 1 visit.  
Table 4: Prohibited Therapi[INVESTIGATOR_178405] 1 (Subjects with FFA)  
Prohibited medications, products, and procedures  Washout period prior to 
first dose  (Day 1)   
Scalp reduction surgery or hair transplantation  - 
Any marketed or investigational biological agent  12 weeks or 5 half -lives 
(whichever is longer ) 
Major surgery  [ADDRESS_209694] or device  4 weeks  
Treatment with agents (including natural products or nutritional 
supplement  such as Viviscal , Nutrafol, and/or biotin ) that may affect hair 
regrowth  4 weeks  
Intralesional scalp corticosteroids or platelet rich plasma injection  4 weeks  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 50 of 82 
Final  Protocol Version 2.0: [ADDRESS_209695] dose  (Day 1)   
Systemic treatments with immunosuppressive/modulating medication or 
medication that could affect FFA (eg, corticosteroids, methotrexate, 
minoxidil, hydroxychloroquine, retinoids, calcineurin inhibitor, 
tetracyclines, pi[INVESTIGATOR_051], spi[INVESTIGATOR_8407] , or 5-α-reductase inhibitors )  4 weeks   
 
JAK inhibitors (systemic o r topi[INVESTIGATOR_2855])  4 weeks  
PUVA treatment , UV -B phototherapy (including tanning beds) or 
excimer laser, any other phototherapy, excessive sun exposure or has 
used tanning booths  [ADDRESS_209696] FFA including, but not 
limited to  topi[INVESTIGATOR_11930], calcineurin inhibitors, minoxidil, 
PDE -4 inhibitors  2 weeks  
Adhesive wigs  During the trial 
Abbreviations: PDE -4, phosphodiesterase -4; FFA, frontal fibrosing alopecia; IMP, investigational medicinal 
product; JAK, Janus -Kinase; PUVA, psoralen -UV-A; UV,  ultraviolet . 
Table 5: Prohibited Therapi[INVESTIGATOR_178371] 2 (Healthy Subjects)  
Prohibited medications, products, and procedures  Washout period prior to 
Day 1   
Any marketed or investigational biological agent  12 weeks or 5 half -lives 
(whichever is longer ) 
Nonbiologial i nvestigational product or device  [ADDRESS_209697] decide to withdraw, all efforts will be made to complete and report the 
observations  as thoroughly as possible , particularly the  examinations outlined in  the ET visit (for 
Cohort 1 only) . 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 51 of 82 
Final  Protocol Version 2.0: [ADDRESS_209698]’s withdrawal should be made with an 
explanation of why the subject is  withdrawing from the trial. If the reason for removal of a subject 
is an AE (or a procedural complication for subjects in Cohort 2) or an abnormal laboratory test 
result, the principal specific event or test will be recorded.  
If a subject  withdraws from the trial, he/she may request destruction of any samples taken and not 
tested, and the investigator must document this in the site study records.  
7.[ADDRESS_209699] assessment ( ET visit) . Subjects who are discontinued for safety reasons may be 
asked to come for additional follow -up visits, at the investigator’s discretion, after the ET visit to 
ensure appropriate medica l care  and AEs follow -up. 
Subjects who discontinue will not be replaced.   
Reasons for discontinuation include  the following : 
• The investigator decides that the subject should be withdrawn. If this decision is made because 
of an SAE , the IMP is to be discont inued in that subject immediately and appropriate measures 
are to be taken. The investigator will notify the sponsor immediately.  
• If an application site reaction occurs, the investigator should use his or her best medical 
judgement as to whether to continu e subject’s treatment.   
• The attending physician requests that the subject be withdrawn from the trial. 
• The subject, for any reason, requires treatment with another therapeutic agent that has been 
demonstrated to be effective for treatment of the trial indication. In this case, discontinuation 
from the trial occurs immediately upon introduction of the new ag ent. 
• The subject is lost to follow -up. In this case, a reasonable attempt to contact [CONTACT_178445] , and these attempts must be documented.  
• The subject becomes p regnan t at any time during the trial.  
• Other: the sub ject may withdraw from the trial for any other reason, including withdrawal of 
consent.  
• The sponsor or regulatory authorities, for any reason, stop the trial. In this case, a ll subjects 
will be discontinued from the trial. The investigator will immediately , on discontinuance of 
the trial by [CONTACT_456], in its entirety or at a clinical trial site, inform both the subjects and the 
research ethics board of the discontinuance, provide them with the reasons for the 
discontinuance and advise them in writing of a ny potential risks to the health of subjects or 
other persons . 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 52 of 82 
Final  Protocol Version 2.0: [ADDRESS_209700]  fails to return to the clinic for a required trial visit:  
• The site will attempt to contact [CONTACT_75359]. The site will 
then counsel the subject on the importance of maintaining the assigned visit schedule and 
ascertain if the subject wishes to or should continue in the trial. 
• Before a subject is deemed lost to follow -up, the investigator or designee will make every 
effort to regain contact [CONTACT_1155] (where possible, three telephone calls and, if 
necessary, a certified letter to the subject’s last known mailing address or  local equivalent 
methods). These contact [CONTACT_9300]’s medical record or 
trial file. 
• If all attempts to contact [CONTACT_18356], he or she will be considered to have withdrawn 
from the trial with a primary reason of lost to follow -up. 
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 53 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  8 TRIAL  ASSESSMENTS  AND PROCEDURES  
8.1  Efficacy As sessments  (Cohort 1 only)  
Clinical evaluations of FFA will be performed by [CONTACT_178446] 
(board certified or equivalent)  or other suitably qualified and experienced designee . To assure 
consistency and reduce variability, the same assessor should perform all assessments on a given 
subject whenever possible . 
 Lichen Planopi[INVESTIGATOR_178406] 1. It is a quantitative measure  of disease 
activity .7 The LPPAI records symptoms (pruritus, pain, burning), signs (erythema, perifollicular 
erythema and scale), a measure of activity (the anagen pull test), and spreading of the condition . 
These subjective and objective measures have been assigned a numeric value to establish a disease 
activity score. The weights given to the symptoms (30%), signs (30%), anagen pull test (25%), 
and presence of spreading (15%) led to the equation: LPPAI  (0-10) = (pruritus + pain +  burning)/3 
+ (scalp erythema + perifollicular erythema + perifollicular scale)/3 + 2.5  (pull test) + 1.5 
(spreading/2).  Symptoms and signs are recorded on a 4 -point scale: 0 =  absent  (negative) , 1 = mild  
(+/-), 2 = moderate  (+), and 3  = severe  (++,+++) . The anagen pull test, when present, is a reliable 
measure of local disease activity. It  involves taking hold of [ADDRESS_209701] from the scalp 
with a perpendicular  force to slide the fingers to the ends of the hair. The result is recorded both 
as a binary  value (0 for no anagen hairs and 1 for the presence of anagen hairs) and as anagen  
hairs/total hairs pulled.  Last is the assessm ent of disease extension, recorded as 0 (no spreading) 
versus 1  (indeterminate) versus 2 (spreading). When the hair loss is difficult to judge, the issue of  
extension is recorded as indeterminate.  A detailed procedure of LPPAI  score calculation is 
provided  in Appendix  A.  
 Frontal Fibrosing Alopecia Severity Score  
The FFASS will be assessed at the visits specified in Table 1. This index is based on the evaluation 
of the relevant clinical features in FFA.8 Those features are the grade of frontal and temporal 
hairline recession (from 1 to 5), grade of eyebrow l oss (none, partial, or total), severity and extent 
of perifollicular erythema and hyperkeratosis, and severity and frequency of pruritus and pain 
associated with FFA. T he resulting severity scores range from 0 to 25, with higher scores 
indicating greater F FA severity.  The clinical features  included in the FFASS are grouped into two 
categories: extent of alopecia (up to 21 points) and inflammation (up to 4 points). A detailed 
procedure of FFASS  score calculation is provided in Appendix  B.  
 Perifollicular Erythema and Scale  
The perifollicular erythema and perifollicular scale  of the selected lesional target area will be 
assessed  visually at the visits specified in Table 1. Each clinical finding (ie, perifollicular erythema 
and perifollicular scale) will be scored  using the 4-point severity scale7,[ADDRESS_209702] a lesional target area with a perifollicular erythema 
score  ≥ 2 and a perifollicular scale score ≥ 2 at Screening and Day 1.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 54 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Table 6: Perifollicular Erythema and Perifollicular Scale Severity Sc ale 
Score  Description  
0 Absent /None  
1 Mild  
2 Moderate  
3 Severe /Intense  
 Pruritus Numeric al Rating Scale   
The intensity of pruritus due to FFA will be recorded using a NRS .10,[ADDRESS_209703] imaginable symptoms . The 
NRS of pain is presented in Appendix  C.  
 Hair Counts/Trichoscopy  
Hair counts/tr ichoscopy will be performed at the visits specified in Table 1. Trichoscopy should 
be performed on the lesional target area, and should not overlap with the site of skin microbiome 
collection. Trichoscopy could overlap with the site of tape strippi[INVESTIGATOR_178407] , but should 
be performed first. The number of hairs, hair diameter, and hair density will be measured via 
fotofinder trichovision.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 55 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 Hair Line Measurements  
Hair line measurements will be performed at the visits specified in Table 1. Lateral canthus (right 
and left) to hairline, lower glabellar crease to hair line, top of frontalis muscle to hair line, and mid 
brow to hair line (right and left)  will be measured using  a disposable paper ruler.  
8.2  Safety Assessments  
 Vital Signs 
The following vital signs will be recorded at the visits specified in Table 1 (Cohort 1) and Table 2 
(Cohort 2) with the subje ct in a seated position, after having sat calmly for at least 5 minutes: 
systolic and diastolic blood pressure (mmHg), pulse (bpm), and body temperature (°C).  
Weight (kg) and height (cm) will be collected at the screening visit. Weight (kg) will also be 
collected at other visits  specified in Table 1 (Cohort 1) and Table 2 (Cohort 2) . 
If deemed appropriate by [CONTACT_093] , clinically significant findings in the vital signs will 
exclude a subject from trial participation.  For Cohort [ADDRESS_209704] be recorded as an AE . 
 Complete Physical Examination  
For subjects in Cohort 1  only, the following sites/systems will at least be included in the  complete  
physical examination , which will be performed at the visits specified in Table 1:  
• General appearance  
• Dermatological ( except FFA) 
• Head, eyes, ears, nose, throat (HEENT)  
• Respi[INVESTIGATOR_696]  
• Cardiovascular  
• Abdominal  
• Neurological  
• Musculoskeletal  
• Lymphatic  
Information for all physical examinations must be included in the source document.  If deemed 
appropriate by [CONTACT_093] , clinically significant findings in the physical examination will 
exclude a subject from trial participation. A ny significant change will be reported as an AE  in the 
source document and eCRF .   
 Brief Physical Examination  
The following sites/systems will at least be included in the  brief physical examination  that will be 
performed at the visits specified in Table 1 (Cohort 1) and Table 2 (Cohort 2) :  
• General appearance  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 56 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  • Dermatological ( except FFA) 
• Respi[INVESTIGATOR_696]  
• Cardiovascular  
• Abdominal  
If deemed appropriate by [CONTACT_178447]’s condition, a complete physical 
examination as described in Section 8.2.[ADDRESS_209705] chemistry panel ( chemistry includes 
liver function tests),  TSH with reflex free T4  (screening), serum pregnancy test (screening) or 
urine pregnancy test (at other visits) for women of childbearing potential (WOCBP). The specific 
tests in these panels are listed in Table 7. 
Table 7: Clinical Laboratory Testing (Cohort 1)  
Laboratory Testing  Tests Included  
Hematology   HCT, Hgb,  MCH, MCHC, MCV, MPV, PLT, RBC, WBC, and differentials 
(neutrophils, lymphocytes, monocytes, eosinophils, and basophils relative 
and absolute)  
Biochemistry  Albumin, alkaline phosphatase, ALT, AST, chloride,  creatinine (enzymatic), 
GGT, glucose random, LDH, potassium, sodium, total bilirubin, 
triglycerides, urea (BUN), uric acid  
Urine pregnancy test  For female  subjects  of childbearing potential (at each visit, except screening)  
Laboratory tests 
required at screening 
only β-hCG for female  subjects of childbearing potential  
Serology (HBV (HBsAg, anti -HBc), HCV, HIV)   
TSH  with reflex free T4 (ie, free T4 will be performed only if TSH value is 
abnormal)  
Abbreviations: ALT , alanine  aminotransferase; anti-HBc, antibody to hepatitis B core antigen ; AST , aspartate 
aminotransferase; β-hCG , β-human chorionic gonadotropin; BUN , blood  urea nitrogen ; GGT , gamma -glutamyl -
transferase; HBsAg , hepatitis B surface antigens; HBV , hepatitis B virus; HCT , hematocrit; HCV , hepatitis C virus; 
Hgb, hemoglobin; HIV, human immunodeficiency virus; LDH ,  lactate  dehydrogenase; MCH , mean corpuscular 
hemoglobin; MCHC , mean corpuscular hemoglobin concentration; MCV , mean corpuscular volume ; MPV , mean 
platelet volume; PLT , platelet s; RBC , red blood cell (count);  TSH, thyroid -stimulating hormone; WBC , white blood 
cell (count).  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 57 of 82 
Final  Protocol Version 2.0: [ADDRESS_209706] from study 
participation (as deemed appropriate by [CONTACT_093]). Any clinically significant value will be 
reported as an AE.  
 Local Tolerability Assessments  
For subjects in Cohort 1,  subject  local tolerability assessments will be performed at the visits 
specified in Table  1. On Day [ADDRESS_209707]’s local tolerability assessment will be done before the IMP application with a recall 
period of 7 days  (worst over the last 7 days ). The subject will evaluate  stinging/burning at the 
application  site using the scale described in Table 8. 
Table 8: Subject Assessment of Local To lerability after IMP Application  
Grade  Stinging/Burning  
0 (none)  No stinging or burning.  
1 (mild)  Slight warm, tingling sensation, not really bothersome.  
2 (moderate)  Definitive warm, tingling sensation, that is somewhat bothersome.  
3 (severe)  Hot, tingling/stinging sensation that has caused definite discomfort.  
Abbreviation: IMP, investigational medicinal product.  
The subject’s assessment of local tolerability may be reported as an AE at the discretion of the 
investigator, even if the investigator does not suspect a local skin reaction related to application of 
IMP (reporting of stinging/burning by [CONTACT_423]).  
8.3  Pharmacodymanic  Assessments  
For subjects in Cohort 1, skin microbiome  samples and skin biopsies  will be collected in all 
subjects. Adhesiv e tape strip samples collection is optional and will be performed per 
investigator ’s judgement (based on available skin area  on the scalp ). However , every effort should 
be made to collect tape strip samples in all subjects . 
For subjects in Cohort 1, it is preferred that the skin microbiome  samples , tape strips  (when 
applicable) , and skin biopsies come from the same lesional target area. If needed, a second lesional 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 58 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  target area could be selected to allow for skin samples collection  and the hair count/tr ichoscopy 
assessment. If two lesional target areas are selected, they should be of similar severity . 
In addition, l esional skin biopsies should be as close as possible from the area of the skin tape 
strippi[INVESTIGATOR_178408] . Lesional skin tape strips could be collected from the 
same area where trichoscopy/hair counts is performed. Other assessments need to be done on 
different areas of the lesional target area(s) (ie, they should not overlap).  
 Skin Biopsies  
The skin will be cleaned, disinfected,  and anesthetized before  skin biopsies are performed. Sterile 
gauze will be used to absorb any bleeding. The biops y sites will be sutured if necessary.  
Details about the collection , processing, handling, storage and shippi[INVESTIGATOR_178409].  
Cohort 1:  
On Day 1, all subjects will have 2 skin biopsies ( 4-mm) collected prior to the first IMP application 
(1 from a lesional hair follicle within the target area and 1 from a non lesional hair follicle [eg, on 
the occipi[INVESTIGATOR_178382]]). On Week 12, 1 skin biopsy ( 4-mm) will be collected from a hair follicle 
within the lesional target area (outside the  scar of previous biopsies). Each biopsy will be split in 
half. One part will be used for IHC and the other part will be used for gene expression analysis .  
Cohort 2: 
On Day 1, all healthy subjects will have 2  skin biopsies ( 4-mm) that include hair follicles collected 
on healthy skin at similar matched areas of subjects with FFA (ie, 1 from frontal  scalp  area and 
1 from occipi[INVESTIGATOR_178383]). Each biopsy will be split in half. One part will be used for IHC and 
the other part will be used for gene exp ression analysis .  
 Tape Strippi[INVESTIGATOR_178410] a non -invasive procedure where superficial skin cells is collected using tape 
strips. For each sampled site, approximately [ADDRESS_209708] same site one afte r the other.  
Details about the collection , handling, storage and shippi[INVESTIGATOR_178411].  
Cohort 1:  
Adhesive tape strip collection is optional for subjects in Cohort 1 and will be collected per 
investiga tor’s judgement (based on available skin area  on the scalp ). However, e very effort should 
be made to collect tape strip samples in all subjects . 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 59 of 82 
Final  Protocol Version 2.0: [ADDRESS_209709] IMP application from lesional skin 
and from nonlesional skin (eg, on the occipi[INVESTIGATOR_178382]) . On Week 12, skin tape strips will be 
collected at the same location of the lesional skin.  
Lesional tape strip samples should ideally be collected in the lesional target  area. However, if the 
lesional target area is not large enough to accommodate the tape strippi[INVESTIGATOR_007], tape strips can be 
collected adjacent/ close to the target area . The tape strip area can be a combination of lesional and 
non lesional skin (or peri -lesional skin) on the scalp , as long as this area  will be  treated with the 
IMP. If possible, tape strippi[INVESTIGATOR_178412] -hair bearing skin.  
Cohort 2: 
On Day 1, skin tape strips will be collected on non-hair bearing healthy skin at a similar matched 
area of subjects with FFA (ie, on the forehead, as close as possible to the  frontal scalp area).  
 Skin Swabs for Microbiomes Analysis  
Collection of skin microbiome samples is a non -invasive procedure where a swab is passed along  
the skin. Skin swabs for microbiome analysis must be collected prior to the tape strippi[INVESTIGATOR_178413].  
Details about the collection , handling, storage and shippi[INVESTIGATOR_178414].  
Cohort 1:  
On Day 1, skin swab for m icrobiome analysis will be collected for all subjects prior to the first 
IMP application (1 from the target area [lesional skin] and 1 from an uninvolved occipi[INVESTIGATOR_178415]). On Week 12, skin microbiome will be collected at the same location of the lesio nal skin of 
the target area . 
Cohort 2: 
Two skin swab samples for microbiome analysis will be collected on healthy skin at similar 
matched areas of subjects with FFA (ie, 1 on frontal scalp area and 1 from occipi[INVESTIGATOR_178383]).  
8.4  Other Assessments  
 Target Area  Identification  
For subjects in Cohort 1 only,  a lesional target area on the scalp (eg, frontal, periauricular , or 
temporal area) and a non lesional area  on the scalp (eg, occipi[INVESTIGATOR_178382]) will be identified. The 
lesional target area  will be within the lesional treated area of FFA and  should be the most active 
area with regards to erythema and scaling as per investigator ’s judgment. To be eligible for this  
trial, subjects must have a lesional target area with a perifollicular erythema score  ≥ 2 and a 
perifollicular scale score ≥ 2 on Day 1.   
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 60 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  To allow for the hair count/trichoscopy assessment and all samples collection (ie, skin biopsies, 
tape strippi[INVESTIGATOR_007], and  skin swabs) , the lesional target area should be approximately 3 cm x 6 cm (or 
equivalent). However, as tape strips can be collected from the same area where trichoscopy/hair 
counts is performed or can be collected adjacent /close  to the lesional target are a (refer to 
Section  8.3.2  for details), a smaller lesional target area may be acceptable. I f needed , two small 
target areas (totalling approximately the same size) could also be selected to allow for skin samples 
collection and hair count/trichoscopy assessment. If two lesional target areas are selected, they 
should be of similar severity.  
In order to mark the lesional target area on the scalp, two [ADDRESS_209710] non -toxic ink in the epi[INVESTIGATOR_178416].  
A note on the location of the lesional target area should be made  in the source document.  
 Medical Photography   
For subjects in Cohort 1 only, medical photographs of the lesional ta rget area  and the entire scalp  
(including the frontal hair line and right and left hair line areas)  will be performed at the visits 
specifie d in Table 1. Photographs should be taken prior to IMP application and skin sample 
collections (ie, skin biopsies, tape strippi[INVESTIGATOR_007] , and skin microbiome ). Photographs will be taken with 
the fotofinder device . Care will be taken to use the same magnification , and the same settings for 
each photograph at each visit in order to obtain comparable pi[INVESTIGATOR_499] .  
Photographs will be identified as follows: trial number, subject number, visit name , and date. 
Photographs will be kept as electronic files on site and will be transmitted to the sponsor for review.  
8.5  Adverse Events and Serious Adverse Events  (Cohort 1  Only ) 
 Definition of Adverse Event   
An AE is any untoward medical occurrence in a subject administered a pharmaceutical product 
and that does not necessarily have a causal relationship with this treatment. An AE can therefore 
be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associ ated with the use of a n IMP, whether or not considered related to the 
IMP. 
 Definition of Treatment -Emergent Adverse Event   
A TEAE is any condition that was not present prior to treatment with the IMP but appeared 
following treatment, was present at treatment initiation but worsened during treatment, or was 
present at treatment initiation but resolved and then reappeared while the individual was on 
treatment (regardless of the intensity of the AE when the treatment was initiated).  
 Definition of Serious Adverse Event   
A SAE  is any untoward medical occurrence that, at any dose has any of the following 
consequences:  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 61 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  • Results in deat h 
• Is life -threatening  
• Requires in -patient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Is a medically important condition. Events that may not be  immediately  
life-threatening or result in death or hospi[INVESTIGATOR_178417]. Examples are intensive treatment in an emergency  
room or at home for allergic bronchospasm, blood dyscrasias, and convulsions  
that do not result in hospi[INVESTIGATOR_18543], development of drug dependency, or drug  
abuse.  
Note: The term “life -threatening” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event that hypothetically 
might have caused death if it were more severe.  
Note: Hospi[INVESTIGATOR_178418].  
Hospi[INVESTIGATOR_5187] a pre -existing condition which did not worsen from  the 
subject consented to trial participation is not considered an AE and  should therefore not  be reported 
as AE or SAE, even if not planned before consent to trial participation.  Hospi[INVESTIGATOR_178419]. Hospi[INVESTIGATOR_178420]. Complications that occur during  hospi[INVESTIGATOR_1084]. If a complication prolongs 
hospi[INVESTIGATOR_18543], the event is an SAE.  When in doubt as to whether hospi[INVESTIGATOR_178421], the AE 
should be considered serious . 
 Classification of an Adverse Event  
[IP_ADDRESS]  Relationship to Trial  Treatment  
The investigator will establish causality of the AE to the experiment al treatment. The investigator 
should take into account the subject’s history, most recent physical examination findings, and 
concomitant medications.  
The following definitions will be used to determine causality of an AE:  
• Not related: Temporal relations hip of the onset of the AE, relative to the experimental 
treatment, is not reasonable, or another cause can explain the occurrence of the AE.  Does 
not reappear or worsen upon re -challenge.  
• Probably Related: Follows a reasonable temporal sequence from admin istration of the IMP. 
Could not be reasonably explained by [CONTACT_423]’s clinical state, environmental or toxic 
factors, or other therapi[INVESTIGATOR_26455]. Follows a known pattern of response 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 62 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  to the IMP. Disappears or decreases on cessation or  reduction in dose of the IMP.  
Reappears or worsens upon re -challenge.  
• Possibly Related:  Follows a reasonable temporal sequence from the administration of the 
IMP. Could also be reasonably explained by [CONTACT_423]’s clinical state, environmental or 
toxic f actors, or other therapi[INVESTIGATOR_26455]. Follows a known pattern of 
response to the IMP.  
[IP_ADDRESS]  Adverse Event Severity  
The intensity of an AE is an estimate of the relative severity of the event made by [CONTACT_178448]. The following definitions 
are to be used to rate the severity of an AE:  
• Mild: The symptom is barely noticeable to the subject and does not influence performance 
of daily activities. Treatment is not ordinari ly indicated.  
• Moderate: The symptom is sufficiently severe to make the subject uncomfortable, and 
performance of daily activities is influenced. Treatment may be necessary.  
• Severe: The symptom causes severe discomfort, and daily activities are significantl y 
impaired or prevented. Treatment may be necessary.  
 
If the AE worsens in severity, the new severity,  including date of severity change, should be 
recorded.  
[IP_ADDRESS]  Outcome  
The outcome  of the event according to the investigator’s clinical judgement should be classified 
using the categories below.  
Recovered/  
resolved  The event has stopped. The stop date of the event must be recorded.  
Recovering/  
resolving  The subject is clearly recoveri ng from an event. The event is not yet completely 
resolved.  
Not 
recovered/  
not resolved  Event is still ongoing.  
Recovered/ 
resolved with 
sequelae  The event has reached a state where no further changes are expected and the 
residual symptoms are assumed to persist. An example is hemiparesis after 
stroke.  
 
The stop date of the event must be recorded. In case of an SAE, the sequelae 
should be specified.  
Fatal  The subject has died as a consequence of the event. Date of death is recorded as 
stop date for the AE.  
Unknown  Unknown to investigator, e.g. subject lost to follow -up. 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 63 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  [IP_ADDRESS]  Expectedness  
Global Safety at LEO Pharma  will assess the expectedness of each SAE in relation to the IMP. 
The relevant reference safety information document for this clinical trial is the delgocitinib  cream  
Investigator’s Brochure, Ed. 4, section 7.3. 
 Time Period and Frequency for Event  Assessment and Follow -Up 
The occurrence of an AE or SAE may come to the attention of trial personnel during trial visits 
and interviews of a trial subject presenting for medical care, or upon review by a trial monitor.  
At all visits, the subject will be asked a non -leading question by [CONTACT_178449],  
eg,: ‘How have you felt since I saw you last?’.  It is i mportant  that the investigator also observes 
the subject for any changes not reported by [CONTACT_178450].  
All AEs, including cutaneous  and systemic reactions, will be captured on the appropriate eCRF. 
Information to be collected includes event description, date of onset, clinician’s assessment of 
severity, relationship to IMP (assessed only by [CONTACT_8703]  a 
diagnosis , ie, the investigator ), and date of resolution/stabilization of the event. All AEs occurring 
while on trial must be documented appropriately regardless of relationship.  
Trial  site personnel will note the occurrence and nature of each subject’ s medical condition(s) 
present prior to the informed consent signature [CONTACT_178491]. During the trial, site personnel will note any change in the condition(s) and the 
occurrence and nature of any AE.  
Any medic al condition that is present prior  to informed  consent signature  [CONTACT_178492]. However, if the trial subject’s condition 
deteriorates after the consent signature , it will be recorded as an AE.  
Should  a subject experience an AE /SAE  at any time after the informed consent signature  [CONTACT_178493], the event will be recorded as an AE in the source document and 
eCRF. The investigator is responsible for appropriate medical  care of subjects during the trial. All 
non-serious AEs will be followed until the last subject’s visit, unless additional follow up is 
required per medical judgment. If an SAE is ongoing at the end of trial, the subject will be followed 
up until the event  is resolved or stable. For SAEs which have stabilized and from which the subject 
cannot be expected to recover during the trial or the safety follow -up period, e .g. chronic or 
stabilized conditions, the final outcome at the investigator’s discretion shoul d be reported as 
‘recovering/resolving’ or ‘not recovered/not resolved’. In addition, a statement detailing why the 
subject cannot be expected to recover during the trial, e.g. that the SAE has stabilized or is chronic, 
should be added to the narrative des cription of the SAE on the SAE form . Follow -up frequency 
will be performed at  the discretion of the investigator .  
Whenever possible, clinically significant abnormal laboratory results are to be reported using the 
diagnostic that resulted in the clinically  significant abnormal laboratory results and not the actual 
abnormal test.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 64 of 82 
Final  Protocol Version 2.0: [ADDRESS_209711] 
may be re -challenged using the assigned trial medication (patch test in the back) to confirm or rule 
out contact [CONTACT_8748].   
 Adverse Event Reporting  
Investigators are responsible for monitoring the safety of subjects who are participatin g in this trial 
and for alerting the sponsor to any event that seems unusual, even if this event may be considered 
an unanticipated benefit to the subject.  
The AE term (verbatim) must be in precise English medical terminology (that is, not necessarily 
the exact words used by [CONTACT_423]). Whenever possible, a specific diagnosis should be stated  (eg, 
‘allergic contact [CONTACT_8748]’).  
For cutaneous AEs, the location of the AE relative to the treatment area will be recorded:  
• Lesional/perilesional (≤2 cm from the border of lesion(s) treated with IMP).  
• Distant (>2 cm from the border of lesion(s) treated with IMP).  
The duration of the AE must be reported by [CONTACT_73320], unless the  
event is ongoing. If the event is ongoing, it will be marked as ongoing. In addition, it will be  
recorded if the AE started prior to first administration of IMP.  
Action taken with IMP : any action taken with IMP as a consequence of the AE must be  recorded 
(dose not changed, drug withdrawn, not applicab le, unknown).  Withdrawal from trial due to this 
AE: it must be recorded whether the AE led to withdrawal  from the trial.  Other action taken: any 
other action taken as a result of the AE must be recorded (none,  concomitant medication, 
concurrent procedure).  
 Serious Adverse Event Reporting  
Global Safety at LEO Pharma  will be the pharmacovigilance unit responsible for the overall 
pharmacovigilance process for this trial. All SAEs, related to the trial treatment or not, occurring 
during the course of the trial must be reported on an SAE form (paper) to Global Safety at LEO 
Pharma  (see below  contact [CONTACT_3031] ) immediat ely without undue delay within 24 hours of the 
knowledge of the occurrence (this refers to any AE that meets one or more of the aforementioned 
serious criteria). This report should  contain amongst others an assessment of available information 
on seriousness, severity, causal  relationship to the IMP or trial procedure, the action taken, the 
outcome to date, and a  narrative description of the course of the event. For more details regarding 
reporting of any  SAE, please see the guidance text on the SAE form.  Additionally, Global Safety 
at LEO Pharma may request further information in order to fully  assess the SAE. The investigator 
must forward such information to LEO Pharma upon request  by [CONTACT_3719] e -mail (see contact s details 
below ). The Innovaderm project team should also be informed of any SAE at the same time as 
Global Safety at LEO Pharma  using the below  contact [CONTACT_3031].  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 65 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  By [CONTACT_178451], the investigator acknowledges that he/she is aware of  the 
SAE and has assessed the causal relationship of the IMP(s) and any of the other  medications to the 
SAE.  
The SAE reporting period ends at the end of the follow -up period . SAEs occurring  after the 
completion of the clinical trial should not be routinely sought or  recorded. However, such events 
should be reported to Global Safety at LEO Pharma and the Innovaderm project team (see contact 
[CONTACT_2212] ) if the investigator becomes aware of them.  
Reporting should be done by [CONTACT_178452] e -mail address es 
(faxing can also be done as a second option in case e -mailing is not possible).  
Safety Contact [CONTACT_7171]: Global Safety at LEO Pharma   
E-mail: drug.safety@leo -pharma.com  
Fax: [PHONE_1914]  
AND  
Innovaderm project team :  
E-mail: [EMAIL_3525]  
Global Safety at LEO Pharma will inform the  LEO  medical monitor  within [ADDRESS_209712] been met.  
Global Safety at LEO Pharma  will manage the expedited reporting of relevant safety information 
to concerned regulatory agencies in accordance with local laws and regulations.   
Investig ators will be notified of the evolving safety profile of the IMP on an ongoing basis  using 
documents such as Investigator Periodic Safety Update and/or any revised version of the IB . 
The investigator must notify the local IRB(s)/IEC(s) of SAEs, as required  by [CONTACT_178453].  
 Pregnancy Reporting  
If a female subject becomes pregnant during the trial and up to [ADDRESS_209713] complete a trial-specific 
pregnancy form upon confirmation of a pregnancy and send i t to Global Safety at LEO Pharma  
within 24 hours of confirmation of the pregnancy (contact [CONTACT_178454])  using the (paper) pregnancy form (part I) . Pregnancy is not itself an AE or 
SAE; however, maternal/fetal com plications or abnormalities will be recorded as AEs or SAEs, as 
appropriate. The investigator will follow the pregnancy until completion or until pregnancy 
termination and, in the case of a live -born offspring, to 1 month of age in that infant. The 
investi gator should notify Global Safety at LEO Pharma  and Innovaderm using the (paper) 
pregnancy form (part II) within [ADDRESS_209714] knowledge  of the outcome as a follow -up to the 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 66 of 82 
Final  Protocol Version 2.0: [ADDRESS_209715]  (AESI)  
An AESI is an event type of scientific and medical concern specific for the product or development 
program , for which additional monitoring may be appropriate. Such an eve nt might warrant further 
investigation in order to further characterize it . 
Deep vein thrombosis/Pulmonary embolism  is considered AESI  in this trial and will require 
additional details to be recorded. LEO Pharma may request that the investigator forward ad ditional 
test results, as appropriate. An AESI may be serious or non -serious. Serious AESIs require 
expedited reported via the SAE form  as described in Section 8.5.7  in addition to the requirements 
specified below.  
The additional information that will be collected is:  
• Risk factors  such as :  
o Previous thromboembolism (record as medical history)  
o Family history of deep vein thrombosis/pulmonary embolism or other 
cardiovascular/blood -clotting disorders  
o Genetic disorders that might increase the risk for thrombosis (record as medical 
history)  
o History of cancer (record as medical history)  
o Recent venous  catheter placement (record as medical history)  
o Current smoker (record as tobacco smoking history)  
o Hormonal contraception/hormonal replacement therapy (record as concomitant 
medication)  
o Trauma or surgery (record as per protocol)  
o Immobilisation (e.g. prolon ged bed rest or sitting for long periods)  
o None  
• Method of verification  may include : 
o Clinical evaluation  
o Image -verified  
o Laboratory test(s)  
 Medication error  
Medication error refers to any unintentional error in the dispensing or administration of an IMP.  
Medication errors include accidental overdose or underdose, inappropriate schedule of product 
administration, incorrect route of product administration, wrong product administered, and expi[INVESTIGATOR_178422].  
Accidental overdose or underdose where a clinical consequence occurred or could have occurred 
should be recorded based on investigator judgement.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 67 of 82 
Final  Protocol Version 2.0: [ADDRESS_209716] occurred should be recorded based on investigator judgement.  
Treatment non -compliance (including missed doses) where no clinical consequence occurred or 
could have occurred should not be recorded as medication errors. See Section 6.3.[ADDRESS_209717] be recorded as separate AEs on  the AE form. If the AE 
originating from the medication error qualifies as an SAE, expedited reporting is required 
(Section  8.5.7 ). 
 Misuse or Abuse  
The terms misuse and abuse are similar in that they both represent the intentional use of a drug in 
a way other than defined in the protocol.  
Misuse refers to situations where the IMP is intentionally and inappropriately used for therapeutic 
purposes not in accordance with the protocol.  
Abuse refers to intentional use of an IMP for what could be considered desirable non -therapeutic 
effects (e.g. sedative, stimulant, euphoric effects).  
Misuse and abuse must be recorded on the AE form in the eCRF. In addition, any clinical 
consequences of misuse or abuse must be recorded as separate AEs on the AE form. If the AE 
originating from the misus e or abuse qualifies as an SAE, expedited reporting is required 
(Section  8.5.7 ). 
 Aggravation of condition  
Any clinically significant aggravation/exac erbation/worsening of any medical condition(s) 
compared to screening must be reported as an (S)AE in accordance with Section  8.5.5 . 
Worsening of FFA is captured by [CONTACT_178455].   
8.6  Procedural Complications (Cohort 2 Only)  
For subjects in Cohort [ADDRESS_209718] that has signed an ICF for the trial, such as infection, bleeding, and/or 
pain, that the investigator believes to be causally related to the trial procedures perfor med at Day  [ADDRESS_209719] medical event 
related to the trial procedures that has any of the following consequences:  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 68 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  • Results in death  
• Is life -threatening  
• Requires in -patient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability/incapacity  
Note: The term “life -threatening” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event that hypothetically 
might have caused death if it were more severe.  
Any medical condition that is present prior to the first sample collection on Day [ADDRESS_209720] experience an event that he believes to be causally related to  the trial procedure performed 
on Day 1 or at the optional follow -up visit (after sample collection), the event will be recorded as 
a procedural  complication. Any procedural complications whether observed by [CONTACT_178456].  
Any serious procedural complication (this refers to any procedural complication that meets one or 
more of the aforementioned serious criteria) occurring during the trial must be reported on a seri ous 
procedural complication form as per the instructions in Section  8.5.7 .  
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 69 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  9 STATISTICAL CONSIDERATIONS  
9.1  Sample Size  Determination  
From Del Duca et al. (2020) paper1, the difference in log2 -fold changes (SD*) between FF A 
patients and healthy controls are reported to 4.851 (4.411), 5.298 (5.512) and 4.559 (4.891) for 
CXCL9, CXCL10 and IFN -γ, respectively.  
A sample 30 subjects are randomized in an equal manner (1:1) to delgocitinib cream 20 mg/g or 
vehicle cream. It is exp ected that a reduction of at least 90% from baseline to Week 12 for the 
delgocitinib cream 20 mg/g treated subjects compared to only 5% in the vehicle group, normalized 
to healthy controls, will be observed.  
With the above assumptions, the trial should hav e at least 80% disjunctive power, i.e. a statistically 
significant difference (tested at 5% one -sided level in an independent two -sample t -test) can be 
shown with at least 80% probability, in at least one of the genes, assuming no correlation between 
the tests and same level of variation  as reported in the Del Duca et al. (2020) paper1. 
*Derived from the reported p -values coming from a t -test comparing lesional FFA biopsy data (N=12) to data from 
healthy controls (N=8) .  
9.2  Populations  for Analyses  
Cohort 1:  
Efficacy will be evaluated on the basis of the full analysis set (FAS ). A supportiv e analysis will 
also be conducted on the per-protocol (PP) analysis set . 
Full analysis set  (FAS) : All subjects randomised and exposed to IMP will be included in the FAS 
and will be analysed based on the randomised treatment allocation. Exclusions from the FAS can 
be considered in special cases as described in ICH E9, Section 5.2.1, Full Analysis Set. If it is 
decided to exclude a subject from the FAS, a justification addressing ICH E9 will be given.  
PD analysis set:  This analysis set  is a subset of the FAS and will include  all subjects who have at 
least one assessment of PD parameters.  
Per-protocol (PP)  analysis set : This analysis set will include a ll subjects who were randomized , 
who received at least one dose of IMP and who at least one post dose efficacy measurement with 
no major protocol deviations affecting the efficacy evaluations . All subjects will be analyzed 
according to the treatment group that they actually received  during the vehicle -controlled period . 
Safety  analysis set  (vehicle -controlled treatment period) : This analysis set will include a ll subjects 
who received at least one dose of the IMP. All subjects will be analyzed according to the treatment 
group that they actually received  during the vehicle -controlled period . 
Safety analysis set  (OLE) : This analysis set will include a ll subjects who entered  the OLE and 
received at least one dose of delgocitinib  20 mg/g  during the OLE .  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 70 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Cohort 2: 
Safety analysis set : This analysis set will include a ll subjects who had at least one skin sample 
collected .  
9.[ADDRESS_209721] deviation  (SD) , median , min imum , max imum , first (Q1) and third (Q3) quartiles . 
Categorical variables will be presented in tables as frequencies and percentages.  
All details regarding the efficacy and safety variable definitions, analyses strategy, statistical 
justification , and techniques for handling missing values will be detailed in a separate statistical 
analysis  plan (SAP) that will be prepared before the databa se is locked and any analyses are  
undertaken.  Any deviation(s) from the SAP will be described an d justified in the final report, as 
appropriate.  Statistical analysis related to molecular signature [CONTACT_178486] /PD analyses  (ie, skin 
biopsies, tape strips, and skin microbiome) will be described in a separate SAP  prepared by [CONTACT_178457] e of these analyses . 
All statistical tests will be two -sided and will be performed with a significant level of 0.05, unless 
otherwise specified in the SAP.  
 Baseline  
Baseline will be defined separately for the vehicle -controlled treatment period and OLE as follows:  
• Vehicle -controlled treatment period:  
For both the safety and exploratory efficacy analyses, t he baseline will be defined as the last 
non-missing assessment prior to the first trial treatment dose (including unscheduled 
assessments). If the last no n-missing assessment is performed on the same date as the first trial 
treatment and time is not available, the assessment will be considered as baseline, except for 
AEs and medications starting on the first trial treatment dose date which will be considere d 
post-baseline.  
• Open -label extension period:  
For the safety analyses, t he OLE baseline will be defined as the last non -missing assessment 
prior to the first delgocitinib cream 20 mg/g dose .  This definition will be used for summarizing 
the change from the OLE baseline for the subject who entered OLE period .    
For the exploratory efficacy analyses, the baseline will be defined as the last non -missing 
assessment prior to the first trial treatme nt dose (including unscheduled assessments)  from the 
vehicle -controlled treatment period  for all subjects . 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 71 of 82 
Final  Protocol Version 2.0: [ADDRESS_209722]-baseline value minus the baseline value unless o therwise specified. Percent change from 
baseline will be  calculated as follows: Percent change from baseline = (Change from baseline / 
Baseline) x [ADDRESS_209723] 7 days prior to 
randomization (prior to the first application of the IMP) . 
 Efficacy Analys es 
[IP_ADDRESS]  Vehicle -Controlled Treatment Period  
The comparison between the groups for the exploratory  efficacy endpoints will be done using a 
mixed model repeated measures (MMRM), where the change from baseline will be the dependent 
variable; the treatment group, the visit, and an interaction term for the treatment -by-visit will be 
the fixed effects; and the baseline value will be the covariate.  
The exploratory efficacy endpoints involving change from baseline will be analyzed at each time 
point using the same approach (i.e., MMRM) as described for the primary efficacy analysis.  
The other efficacy endpoin ts involving proportions of pruritus NRS, burning sensation NRS, and 
pain NRS will be analyzed using a Chi -squared test at each visit.  
The primary efficacy analysis will be done using the FAS, and the PP analysis set will be used as 
supportive analysis. N o imputation will be performed for the continuous endpoints subjected to an 
MMRM.  
For the analyses of binary data, imputation of the last observation carried forward (LOCF) for any 
missing value will be performed.  
[IP_ADDRESS]  Open -Label Extension Period  
These efficacy outcomes will be measured at scheduled visits after Week 12 . The following 
endpo ints will be assessed in the OLE:  
• Continuous variables: observed value and change (percent) from baseline in  LPPAI, 
FFASS, target area perifollicular scale score, target area perifollicular erythema score, 
pruritus NRS, burning sensation NRS, pain NRS, and  target area hair counts/trichoscopy 
via fotofinder trichovision.  
The above endpoints will be summarized by [CONTACT_178458]:  
• Summaries will be provided for 1 ) treatment group in OLE and for 2 ) randomized tr eatment 
groups in the vehicle -controlled treatment period.  
• Change from baseline in continuous variables will be analyzed using change from 
vehicle -controlled treatment period baseline . 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 72 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 Safety Analys es 
[IP_ADDRESS]  Vehicle -Controlled Treatment Period  
Cohort 1:  
All safety data, including AEs and SAEs  will be presented and tabulated according to the Medical 
Dictionary for Regulatory Activities (MedDRA ) classification. Descriptions of AEs will include 
the start date , the stop date  (if it resolved), the severity and seriousness of the AE, the causality of 
the AE to IMP, and the outcome. The focus in this protocol will be the number  of 
treatment -emergent adverse events  (TEAEs) . 
Adverse events will be considered in vehicle -controlled treatment period or OLE depending on the 
onset date – if the AE onset date was before Week 12, the AE will be considered as a 
vehicle -controlled treatment period AE. If the AE had an onset on or after Week 12, the AE will 
be considered as an OLE AE.   
Repor ted AEs will be summarized by [CONTACT_178459], as well as by 
[CONTACT_1196]  (SOC) , PT, severity, seriousness, and relationship to IMP. For the summary 
of AEs by [CONTACT_926], each subject  will be counted only once within a SOC  or a PT by [CONTACT_178460]. For the summary of AEs by 
[CONTACT_178461], each  subject  will be counted only once within a SOC  or a PT by [CONTACT_178462] w ithin each category. For the summary of AEs by 
[CONTACT_178463], each subject  will be counted only once within a SOC  or a PT by 
[CONTACT_2329] (1) the greatest reported relationship followed by (2) the highest reported intensity.  
All information per taining to AEs noted during the trial will be listed by [CONTACT_1130] , detailing 
verbatim, SOC , PT, start date, stop date, intensity, outcome , and relationship to IMP. The AE onset 
will also be shown relative (in number of days) to the day of IMP administration. Serious adverse 
events will be tabulated by [CONTACT_1570], relationship to the IMP, and a reference to the 
occurrence of the SAEs to the relative day of dosi ng. 
AESIs will be listed. No narratives for AESIs will be written in the study report .  
Results from laboratory analyses  and vital signs  will be tabulated by [CONTACT_178464]. The value at each visit as well as the change fr om baseline will be presented 
descriptively.  
Clinically significant changes in laboratory analyses  and vital signs , and new findings on local 
tolerability assessments and physical examination will be recorded as AEs.  
Concomitant medications will be coded w ith the world health organization  (WHO )-Drug 
Dictionary and listed by [CONTACT_1130].  Summary of medication classes will also be tabulated.  
No inferential statistics will be done on safety variables.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 73 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  Cohort 2: 
Procedural complications  will be presented and tabulated according to MedDRA classification. 
Descriptions of procedural complications will include the start date , the stop date  (if it resolved), 
the severity and seriousness of the procedural complication , and the outcome.  
Report ed procedural complications  will be summarized by [CONTACT_178465], as well as by [CONTACT_2946] , PT, severity, and seriousness. For the summary of procedural 
complications  by [CONTACT_926], each subject  will be counted only once within a SOC  or a PT by [CONTACT_178466].  
All information pertaining to procedural complications  noted during the trial will be listed by 
[CONTACT_1130] , detailing verbatim, SOC , PT, start date , stop date, intensity, and outcome. The procedural 
complication  onset will also be shown relative (in number of days) to the Day 1 skin sample 
collection .  
[IP_ADDRESS]  Open -Label Extension Period  
Safety analyses will follow general considerations in previous Section [IP_ADDRESS]  with the following 
exceptions:  
• Summaries will be provided for 1) treatment group in the OLE and for 2) randomized 
treatment groups in vehicle -controlled treatment period.  
• Change from baseline will be analyzed using change from vehicle -controlled treatment 
period baseline for subjects who received delgocitinib during the vehicle -controlled 
treatment period, and change from OLE baseline for subjects who received placebo during 
the vehicle -control led treatment period.  
Only descriptive statistics will be presented.  
 Molecular Signature [CONTACT_178494] . A 
MMRM will be used to detect any overall differences in the treatment effect at Week [ADDRESS_209724]. T his approach introduces less bias than 
restricting the analysis for those patients who completed the trial. Time points (baseline, Week 
12), treatment group (active, vehicle , and healthy) , and tissue (lesional and non -lesional) will be 
considered as fixed factors, while participant ID will be included as random factor.  
 Other Analyses  
Descriptive summaries of baseline charact eristics, including demographic data , prior and 
concomitant therapy , and subject disposition will be presented. In addition, a li st of subjects who 
discontinued fro m the trial will be provided . 
Protocol deviations will be summarized by [CONTACT_178467].  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 74 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 Planned Interim Analys es 
No interim analysis is planned in this trial. 
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 75 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  10 REGULATORY, ETHICAL, AND TRIAL  OVERSIGHT 
CONSIDERATIONS  
10.1  Local Regulations/Declaration of Helsinki  
This trial will be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and that are consistent with ICH Tripartite Guideline for GCP and the 
applicable laws  and regulations of the country in which the research is conducted, whichever 
affords the greater protection to the individual.  
10.2  Ethical Review  
It is the understanding of the sponsor that this protocol (and any amendments) as well as 
appropria te consent procedures, will be reviewed and approved by a REB/IRB. This board must 
operate in accordance with the current federal regulations. If the site has  a local ethics committee, 
a letter or certification of approval will be sent by [CONTACT_68477] (or CRO) before 
initiation of the trial and also whenever subsequent modifications to the protocol are made.  
10.3  Informed Consent Process  
An ICF describing in detail the trial treatment  (for C ohort 1 only) , trial procedures, and risks will 
be given to the subject, along with an assent form when required.  
It is the responsibility of the investigator, or a person designated by [CONTACT_093] (if acceptable 
by [CONTACT_1295]), to obtain written informed consent from each individual participating in this 
trial, after adequate explanation of the aims, metho ds, objectives, and potential hazards of the trial. 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
trial and continues throughout the individual’s trial participation. Consent forms will be IRB /REB  
approved, and the subject will be asked to read and review the document. The investigator will 
explain the research trial to the subject and answer any questions that may arise. A verbal 
explanation will be provided in terms suited to the subject’s compreh ension of the purposes, 
procedures, and potential risks of the trial and of his or her rights as a research subject. Subjects 
will have the opportunity to carefully review the written consent form and ask questions prior to 
signing. The subjects should hav e the opportunity to discuss the trial with their family or surrogates 
or think about it prior to agreeing to participate.  
The subject will sign the informed consent document prior to any procedures being done 
specifically for the trial. Subjects must be i nformed that participation is voluntary and that they 
may withdraw from the trial at any time  for any reason , without prejudice. A copy of the signed  
informed consent document will be given to the subjects for their records. The informed consent 
process wi ll be conducted and documented in the source document (including the date), and the 
form signed, before the subject undergoes any trial-specific procedures.  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 76 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  The rights and welfare of the subjects will be protected by [CONTACT_178468]. 
If new safety information results in significant changes in the risk/benefit assessment, or if any 
new information becomes available that may affect the willin gness of a subject to continue to 
participate, the consent form should, if necessary, be reviewed and updated by [CONTACT_1201] /REB . All 
subjects (including those already being treated) should be informed of the new information, given 
a copy of the revised form, and asked to give their consent to continue in the trial. 
10.[ADDRESS_209725] s and  the IRB /REB , and will provide the reason(s) 
for the termination or suspension. Trial  subjects will be contact[INVESTIGATOR_530], as applicable, and be informed 
of changes to  trial visit schedule.  
Circumstances that may warrant termination or suspension of the trial include, but are not limited 
to the following:  
• Determination of unexpected, significant, or unacceptable ris k to subjects  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete or evaluable  
• Scientific or corporate reasons  
The trial may resume once concerns about safety, protocol compliance, and data quality are 
addressed and sat isfy the sponsor, IRB /REB , and/or FDA.  
10.[ADDRESS_209726] assure that the subjects’ anonymity will be maintained and that subjects’ 
identities are protected from unauthorized parties. On CRF  or other documents submitted to the 
sponsor, subjects should not be identified by [CONTACT_2249], but by [CONTACT_1209]. The 
inves tigator should keep a subject log relating codes with the names of subjects. The investigator 
should maintain in strict confidence documents not for submission to LEO Pharmaceutical A/S  
(e.g., subjects’ written consent forms).  
All research activities will be conducted in a setting as private as possible.  
The study monitor, other authorized representatives of the sponsor, and representatives of the IRB, 
regulatory agencies, or pharmaceutical company supplying IMP may inspect all documents and  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 77 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  records required to be maintained by [CONTACT_093], including but not limited to, medical records 
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this trial. The clinical site will 
permit access to such records.  
The trial subject’s contact [CONTACT_178469]. At the end of the trial, all records will continue to be kept in a secure location for 
as long a period as dictated by [CONTACT_178470] r egulatory requirements, the reviewing IRB, 
institutional policies, or sponsor requirements.  
10.6  Clinical Monitoring  
Clinical site monitoring will be conducted to ensure that the rights and well -being of trial subjects 
are protected; that the reported trial da ta are accurate, complete, and verifiable; and that the conduct 
of the trial is in compliance with the currently approved protocol/amendment(s), ICH GCP 
guidelines, and with applicable regulatory requirement(s). Details of clinical site monitoring will 
be documented in a Monitoring Plan.  Centralized monitoring, which consist of remote review of 
accumulating data from all sites, will be performed as detailed in the Centralized Monitoring Plan .  
10.[ADDRESS_209727], data and biological 
specimen collection, documentation, and completion.  
Quality control (QC) procedures will be implemented beginning with the data entry system, and 
data QC checks, which will be run on the database, will be generated. Any missing data or data 
anomalies will be communicated to the site(s) for clarification/resolution.  
During the trial, the sponsor or its representative will conduct monitoring visits at regular intervals. 
The monitoring vi sits will be conducted to ensure protocol adherence, quality of data, accuracy of 
entries on the eCRFs , IMP accountability, compliance with regulatory requirements, and continued 
adequacy of the site and its facilities.  
The site may be audited, monitored, or inspected by a quality assurance officer named by [CONTACT_103], by [CONTACT_178471], and/or by [CONTACT_50756]. The investigator will be given 
notice before an audit occurs and will be expected to cooperate with any audit and provide 
assistance and documentation (including source data) as requested. The site will provide direct 
access to all trial -related sites, source data/documents, and reports for the purpose of monitoring 
and auditing by [CONTACT_178472].  
10.[ADDRESS_209728] of the trial to 
be fully documented and the trial data to be subsequently verified. These documents should be 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 78 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  classified into two separate categories: investigator’s study files and subject clinical source 
documents.  
The investigator must maintain source documents for each subject in the trial. These source 
documents will consist of case and visit notes (clinical medical records) containing d emographic 
and medical information and the results of any tests or assessments. All information on the eCRFs  
must be traceable to the source documents in the subject’s file. Data not requiring a written or 
electronic record will be defined before trial start and will be recorded directly on the eCRFs , 
which will be documented as being the source data.  
The records should be retained by [CONTACT_178473], local regulations, 
or as specified in the Clinical Trial Agreement, w hichever retention period is longer.  
Subject data will be entered by [CONTACT_178474] , a web-based EDC and reporting 
system. This application will be set up for remote entry. Medrio Inc. is the developer and owner 
of Medrio . The EDC software has  been fully validated and conforms to Title [ADDRESS_209729], the investigator, or the trial site staff. As 
a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
The clinical research associate ( CRA ) must ensure that a prompt action is taken to secure 
compliance. If a non -compliance that significan tly affects or has the potential to significantly affect 
human subject protection or reliability of trial results is discovered, the CRO and the Sponsor 
should perform a root cause analysis and implement appropriate corrective and preventive actions . 
Proto col deviations must be sent to the reviewing IRB per their policies. The investigator is 
responsible for knowing and adhering to the reviewing IRB requirements.  
10.[ADDRESS_209730] being dosed.   
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 79 of 82 
Final  Protocol Version 2.0: [ADDRESS_209731] T 
helper 1 and Janus kinase 3 skewing. Br J Dermatol. 2020;183(6):1083 -1093.  
2. Imhof R, Tolkachjov SN. Optimal Management of Frontal Fibrosing Alopecia: A Practical 
Guide. Clin Cosmet Investig Dermatol. 2020;13:[ADDRESS_209732], Hosking AM, Cox S, Mesinkovska NA. Therapeutic response of facial papules 
and inflammation in frontal fibrosing alopecia to low -dose oral isotretinoin. JAAD Case 
Rep. 2020;6(5):453 -456. 
4. Harries  MJ, Meyer K, Chaudhry I, et al. Lichen planopi[INVESTIGATOR_178423]'s epi[INVESTIGATOR_178424]. J Pathol. 2013;231(2):236 -
247. 
5. Investigator's Brochure Delgocitinib Cream. In. Vol Edition no. 04: LEO Pharma A/S; 22 -
Jan-2021.  
6. Tavakolpour S, Mahmoudi H, Abedini R, Kamyab Hesari K, Kiani A, Daneshpazhooh M. 
Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment. Int 
J Womens Dermatol. 2019;5(2):116 -123. 
7. Chiang C, Sah D , Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen 
planopi[INVESTIGATOR_22785]: efficacy and introduction of Lichen Planopi[INVESTIGATOR_178425]. J Am Acad Dermatol. 2010;62(3):387 -392. 
8. Saceda -Corralo D, Moreno -Arrones OM, Fonda -Pascual P, et al . Development and 
validation of the Frontal Fibrosing Alopecia Severity Score. J Am Acad Dermatol. 
2018;78(3):522 -529. 
9. Doche I, Romiti R, Hordinsky MK, Valente NS. "Normal -appearing" scalp areas are also 
affected in lichen planopi[INVESTIGATOR_178426]: An observational 
histopathologic study of 40 patients. Exp Dermatol. 2020;29(3):278 -281. 
10. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on 
validity and reliability of the visual analogue scale, nume rical rating scale and verbal rating 
scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502 -507. 
11. Verweyen E, Stander S, Kreitz K, et al. Validation of a Comprehensive Set of Pruritus 
Assessment Instruments: The Chronic Pruritus Tools Questionnaire PRURITOOLS. Acta 
Derm Venereol. 2019;99(7):657 -663. 
12. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog 
Scale fo r Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain 
Questionnaire (MPQ), Short -Form McGill Pain Questionnaire (SF -MPQ), Chronic Pain 
Grade Scale (CPGS), Short Form -36 Bodily Pain Scale (SF -36 BPS), and Measure of 
Intermittent and Const ant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 
2011;[ADDRESS_209733] 11:S240 -252. 
13. Haefeli M, Elfering A. Pain assessment. Eur Spi[INVESTIGATOR_050] J. 2006;[ADDRESS_209734] 1:S17 -24. 
14. European Parliament Union. European CoT. Directive 2001/20/EC of the European 
Parliament and of the Council of [ADDRESS_209735] of clinical trials on medicinal products for  human use. EMA 
ed 2001. 2001.  
 
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 80 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX  A: Lichen Plan opi[INVESTIGATOR_178370]  (LPPAI)  7 
 
  
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 81 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX  B: Frontal Fibrosing Alopecia Severity Score  8  
 
TMF-000674983 - Version 2.0
LEO  Pharma A /S – Protocol EXP -2228  Page 82 of 82 
Final  Protocol Version 2.0: 17 November 2021  
 
. 
Confidential and proprietary. Permission should be obtained before any reproduction.  APPENDIX  C: Numerical Rating  Scale  
Pruritus NRS  
On scale from 0 (“no itch”) to 10 (“worst imaginable itch”), how was your worst itch due to 
your frontal fibrosing alopecia in the past 24 hours? Please select one number.   
Numeric Rating Scale   
   
[ADDRESS_209736] imaginable itch  
 
 
Modified  from : http://www.pruritussymposium.de/numericalratingscale.html  
 
Burning Sensation NRS  
On scale from 0 (“no burning sensation ”) to 10 (“worst imaginable burning sensation ”), how 
was your worst burning sensation  due to your frontal fibrosing alopecia  in the past 24 hours? 
Please select one number.   
Numeric Rating Scale   
   
[ADDRESS_209737] imaginable burning sensation  
 
 
Pain NRS  
On scale from 0 (“no pain ”) to 10 (“worst imaginable pain ”), how was your worst  pain  due 
to your frontal fibrosing alopecia  in the past 24 hours? Please select one number.   
Numeric Rating Scale   
   
[ADDRESS_209738] imaginable  pain 
 
 
TMF-000674983 - Version 2.0
Certificate Of Completion
Envelope Id: 2C4E0C467E6D413A911CC90B0FA4DE36 Status: Completed
Subject: Veuillez signer avec DocuSign : EXP2228_Protocol_V2.0_Final 17-NOV-2021_clean.pdf
Source Envelope: 
Document Pages: 82 Signatures: 7 Envelope Originator: 
Certificate Pages: 7 Initials: 0
AutoNav: Enabled
EnvelopeId Stampi[INVESTIGATOR_007]: Disabled
Time Zone: (UTC-05:00) Eastern Time (US & Canada)
IP Address: [IP_ADDRESS]  
Record Tracking
Status: Original
             17-Nov-2021 | 17:43Holder:
           Location: DocuSign
Signer Events Signature [CONTACT_178495]: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Drawn on Device
Signature [CONTACT_5883]: 
D3356B70-2B46-4F39-96DE-FC44215D8354
Using IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 17-Nov-2021 | 17:52
Resent: 18-Nov-2021 | 14:51
Viewed: 18-Nov-2021 | 14:51 
Signed: 18-Nov-2021 | 14:[ADDRESS_209739] and Signature [CONTACT_59773]: 
      Accepted: 15-Nov-2021 | 09:55
      ID: 00b0ec9b-c7b7-4e9a-970c-97492e4afa9d
Security Level: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Drawn on Device
Signature [CONTACT_5883]: 
DB7D53CA-C36E-4C84-9A64-C5079958AE57
Using IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 18-Nov-2021 | 14:52
Viewed: 22-Nov-2021 | 10:07 
Signed: 22-Nov-2021 | 10:[ADDRESS_209740] and Signature [CONTACT_59773]: 
      Accepted: 19-May-2021 | 18:27
      ID: f373dc0f-a381-45bf-988b-4efb86e0d6e7TMF-000674983 - Version 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Signer Events Signature [CONTACT_178495]: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Drawn on Device
Signature [CONTACT_5883]: 
F2819AA0-2D85-4544-8966-ED63996977AF
Using IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 22-Nov-2021 | 10:08
Resent: 22-Nov-2021 | 10:54
Resent: 22-Nov-2021 | 10:54
Viewed: 22-Nov-2021 | 10:55 
Signed: 22-Nov-2021 | 10:[ADDRESS_209741] and Signature [CONTACT_59773]: 
      Accepted: 22-Nov-2021 | 10:55
      ID: b56b33f9-469d-4c6f-b4f0-fe9dd669a06a
Security Level: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Pre-selected Style
Signature [CONTACT_5883]: 
94703ED9-E9E9-4772-915A-087286411469
Using IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 22-Nov-2021 | 10:56
Viewed: 22-Nov-2021 | 10:57 
Signed: 22-Nov-2021 | 10:[ADDRESS_209742] and Signature [CONTACT_59773]: 
      Accepted: 09-Jun-2021 | 15:25
      ID: 83200eef-5826-4f7a-a13d-a4de5196b433
Security Level: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Pre-selected Style
Signature [CONTACT_5883]: 
D6757230-808F-4E58-BF63-98469075EDC1
Using IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 22-Nov-2021 | 10:58
Viewed: 22-Nov-2021 | 11:21 
Signed: 22-Nov-2021 | 11:[ADDRESS_209743] and Signature [CONTACT_59773]: 
      Accepted: 10-Jun-2021 | 04:53
      ID: 7a8e855f-fc87-482a-984c-152ad63e74aaTMF-000674983 - Version 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Signer Events Signature [CONTACT_178496], Scientific and Reg Affairs
Security Level: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Pre-selected Style
Signature [CONTACT_5883]: 
7B587BB5-D178-4033-A925-A4345557A0A4
Using IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 22-Nov-2021 | 11:22
Viewed: 22-Nov-2021 | 11:40 
Signed: 22-Nov-2021 | 11:[ADDRESS_209744] and Signature [CONTACT_59773]: 
      Accepted: 22-Nov-2021 | 11:40
      ID: 662f227f-d629-434e-b7d5-729aa1fa6831
Security Level: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Pre-selected Style
Signature [CONTACT_5883]: 
D96D4D3C-2ADE-46CE-A93C-89D6469C1E56
Using IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 22-Nov-2021 | 11:40
Viewed: 22-Nov-2021 | 12:42 
Signed: 22-Nov-2021 | 12:[ADDRESS_209745] and Signature [CONTACT_59773]: 
      Accepted: 22-Nov-2021 | 12:42
      ID: 72b38ff3-4b2b-4fe0-8c35-15615237febd
In Person Signer Events Signature [CONTACT_178497]: Email, Account Authentication 
(Required)
Sent: 22-Nov-2021 | 12:43
Viewed: 22-Nov-2021 | 12:[ADDRESS_209746] and Signature [CONTACT_59773]: 
      Accepted: 19-Nov-2021 | 16:05
      ID: 20b5e11f-945a-47a3-a34a-06bfb116b4eb
Witness Events Signature [CONTACT_178498]-000674983 - Version 2.0
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Envelope Summary Events
Status
Timestamps
Envelope SentHashed/Encrypted17-Nov-2021 | 17:52
Certified DeliveredSecurity Checked22-Nov-2021 | 12:42
Signing CompleteSecurity Checked22-Nov-2021 | 12:43
CompletedSecurity Checked22-Nov-2021 | 12:[ADDRESS_209747] and Signature [CONTACT_178499]-000674983 - Version 2.0
CONSUMER DISCLOSURE
From time to time, Innovaderm Research Inc. (we, us or Company) may be required by [CONTACT_178475]. Described below are the terms and
conditions for providing to you such notices and disclosures electronically through the
DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below
carefully and thoroughly, and if you can access this information electronically to your
satisfaction and agree to these terms and conditions, please confirm your agreement by [CONTACT_178476] â€˜I agreeâ€™ button at the bottom of this document. 
Getting paper copi[INVESTIGATOR_174510], you may request from us a paper copy of any record provided or made available
electronically to you by [CONTACT_3019]. You will have the ability to download and print documents we send
to you through the DocuSign system during and immediately after signing session and, if you
elect to create a DocuSign signer account, you may access them for a limited period of time
(usually 30 days) after such documents are first sent to you. After such time, if you wish for us to
send you paper copi[INVESTIGATOR_81411], you will be charged a
$0.[ADDRESS_209748]
withdraw your consent using the DocuSign â€˜Withdraw Consentâ€™ form on the signing page
of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn
your consent to receive required notices and disclosures electronically from us and you will no
longer be able to use the DocuSign system to receive required notices and consents electronically
from us or to sign electronically documents from us. 
All notices and disclosures will be sent to you electronically
Unless you tell us otherwise in accordance with the procedures described herein, we will provide
electronically to you through the DocuSign system all required notices, disclosures,
authorizations, acknowledgements, and other documents that are required to be provided or
made available to you during the course of our relationship with you. To reduce the chance of
you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required
notices and disclosures to you by [CONTACT_178477]. Thus, you can receive all the disclosures and notices electronically or in paper format through
the paper mail delivery system. If you do not agree with this process, please let us know as
described below. Please also see the paragraph immediately above that describes the
consequences of your electing not to receive delivery of the notices and disclosures
Electronic Record and Signature [CONTACT_81486]: 22-Nov-2016 | 16:[ADDRESS_209749] Innovaderm Research Inc.: 
You may contact [CONTACT_178478] a s to how we may contact [CONTACT_81482], 
to request paper copi[INVESTIGATOR_178427], and to withdraw your prior consent to 
receive notices and disclosures electronically as f ollows: 
 To contact [CONTACT_178479]: fbogusiak @innovaderm.ca 
To advise Innovaderm Research Inc. of your new e-ma il address 
To let us know of a change in your e-mail address w here we should send notices and disclosures 
electronically to you, you must send an email messa ge to us at [EMAIL_3526] and in 
the body of such request you must state: your previ ous e-mail address, your new e-mail address.  
We do not require any other information from you to  change your email address..  
In addition, you must notify DocuSign, Inc. to arra nge for your new email address to be reflected 
in your DocuSign account by [CONTACT_178480] f or changing e-mail in the DocuSign system. 
To request paper copi[INVESTIGATOR_178428] c. 
To request delivery from us of paper copi[INVESTIGATOR_81414], you must send us an e- mail to [EMAIL_3526] and in the 
body of such request you must state your e-mail add ress, full name, US Postal address, and 
telephone number. We will bill you for any fees at that time, if any. 
To withdraw your consent with Innovaderm Research I nc. 
To inform us that you no longer want to receive fut ure notices and disclosures in electronic 
format you may: 
i. decline to sign a document from within your Docu Sign session, and on the subsequent 
page, select the check-box indicating you wish to w ithdraw your consent, or you may; 
ii. send us an e-mail to [EMAIL_3526] an d in the body of such request you 
must state your e-mail, full name, US Postal Addres s, and telephone number. We do not 
need any other information from you to withdraw con sent..  The consequences of your 
withdrawing consent for online documents will be th at transactions may take a longer time 
to process.. 
Required hardware and software 
Operating Systems: WindowsÂ® 2000, WindowsÂ® XP, Windows 
VistaÂ®; Mac OSÂ® X 
Browsers: Final release versions of Internet ExplorerÂ® 
6.0 or above (Windows only); Mozilla Firefox 
2.0 or above (Windows and Mac); Safariâ„¢ 
3.0 or above (Mac only) 
PDF Reader: AcrobatÂ® or similar software may be required 
to view and print PDF files 
Screen Resolution: 800 x 600 minimum 
Enabled Security Settings: Allow per session cookies 
 
** These minimum requirements are subject to change . If these requirements change, you will be 
asked to re-accept the disclosure. Pre-release (e.g . beta) versions of operating systems and 
browsers are not supported. 
Acknowledging your access and consent to receive ma terials electronically 
TMF-[ADDRESS_209750] it for
your future reference and access. Further, if you consent to receiving notices and disclosures
exclusively in electronic format on the terms and conditions described above, please let us know
by [CONTACT_17325] â€˜I agreeâ€™ button below. 
By [CONTACT_174542] â€˜I agreeâ€™ box, I confirm that: 
• I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF
ELECTRONIC CONSUMER DISCLOSURES document; and
• I can print on paper the disclosure or save or send the disclosure to a place where I can
print it, for future reference and access; and
• Until or unless I notify Innovaderm Research Inc. as described above, I consent to receive
from exclusively through electronic means all notices, disclosures, authorizations,
acknowledgements, and other documents that are required to be provided or made
available to me by  [CONTACT_178481]. during the course of my relationship with
you.
TMF-000674983 - Version 2.0